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AUGMENTATION OF RAS-INDUCED CELL TRANSFORMATION: 
A NEW ROLE FOR MIR-200A IN MALIGNANCY 
 
Lindsey Erin Becker 
April 2, 2014 
 
Cancer is a multistep disease that begins with malignant cell transformation and 
frequently culminates in metastasis and death.  MicroRNAs (miRNAs) are small 
regulatory 21-25-nt RNA molecules and are frequently deregulated in cancer.  The 
majority of miRNAs are estimated to be co-expressed with neighboring miRNAs as 
clusters. Many miRNA clusters coordinately regulate multiple members of cellular 
signaling pathways or protein interaction networks.  miR-200a is a member of the miR-
200 family, which are known to be strong inhibitors of the epithelial to mesenchymal 
transition.  As such, the tumor suppressive role of miR-200a in oncogenesis has been well 
studied; however, recent studies have found a proliferative role for this miRNA as well as 
a pro-metastatic role in the later steps of cancer progression. In this study, we employed a 
biphasic approach to determine miRNA involvement in malignant cell transformation. 
First, we screened 366 human miRNA minigenes to determine their effects on the four 




transcriptional activity. The second phase of this study was an epithelial cell screening 
assay to determine the ability of miRNAs to transform epithelial cells. In our miRNA 
cluster profiling study, we found that miR-200a down-regulates p53 activity.  miR-200a 
was demonstrated to directly target p53, reduce protein levels, and inhibit apoptosis. We 
also found that miR-200a enhances Ras-mediated transformation of MCF10A cells.  
Furthermore, miR-200a transforms MCF10A cells and induces tumorigenesis in 
immunocompromised mice by cooperating with a Ras mutant that activates the RalGEF 
effector pathway. These results demonstrate a role for miR-200a in malignant 
transformation and reveal a specific cellular environment in which miR-200a acts as an 
oncomiR rather than a tumor suppressor by cooperating with oncogene activation in the 
classical two hit model of cell transformation.  
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INTRODUCTION: CANCER AND MICRORNAS 
Cancer Statistics and Cancer Progression 
One in three Americans will be diagnosed with cancer in his or her lifetime.  In 
2013, an estimated 1.6 million new cases of cancer were diagnosed, and over half a 
million Americans died of cancer.  It is the number two leading cause of death in the 
United States, accounting for nearly one in every four deaths.  The most frequently 
occurring cancers in men are prostate, lung, and bladder.  In women, the most frequently 
occurring cancers are those arising in the breast, digestive system, and respiratory system.  
In both men and women combined, lung cancer was responsible for 159,480 deaths in 
2013, over a third of all cancer related deaths.  The second most deadly cancers in men 
and women are prostate and breast, respectively.  Colon cancer claims the third most 
lives for both sexes.  Despite these grim numbers, cancer death rates are declining in both 
sexes [1].  In 2009 alone, 152,900 cancer related deaths were avoided, thanks in part to 
advances in treatment efficacy.  Even more important, however, are advances in detecting 
and diagnosing cancer at early, more treatable stages [2,3].   
There are multiple forms of cancer, classified by the cell type from which they 




bladder—are examples of carcinomas, or cancers arising from epithelial cells. 
Carcinomas are the most common form of cancer. 
Cancer is comprised of a progressive series of steps, beginning with malignant 
cell transformation, which leads to primary tumor formation.  Vascularization of the 
tumor occurs to allow survival and growth.  Tumor cells become invasive and motile by 
undergoing an epithelial to mesenchymal transition (EMT).  During this process, 
epithelial cells, once constrained by the necessity of cell:cell and cell:basement 
membrane contacts for survival, experience changes in gene expression that result in an 
elongated, mesenchymal phenotype and the ability to migrate and invade local stroma 
[4].  This mobile, mesenchymal phenotype also allows for subsequent intravasation of 
invasive cancer cells into the blood stream, allowing them to circulate throughout the 
body. Circulating cancer cells will then extravasate from the blood stream to colonize 
new sites on distal tissues.  New studies have shown the importance of the reversal of 
EMT, the mesenchymal to epithelial transition (MET), in metastatic colonization at distal 
sites [5-7].  By developing a more stable epithelial phenotype, cells that were once 
mobile and invasive acquire the characteristics necessary for formation of a secondary 
metastatic tumor.  It is rarely the primary tumor that is responsible for cancer mortalities, 
but rather the late stage metastatic disease that accounts for over 90% of cancer related 
deaths [8-10].  The study of the very first step of cancer progression—cell 
transformation—is thus crucial to provide the means for diagnosing and treating cancer 




Malignant Cell Transformation 
Malignant cell transformation occurs when a normal somatic cell develops the 
ability to proliferate indefinitely and escape the cell cycle control checkpoints and 
apoptotic signaling that normally eliminate cells with hyper-activated proliferative 
signaling pathways [11].  Cells that acquire this unrestrained proliferation phenotype in 
vivo can develop into a tumor.  In 2000, Robert Weinberg elegantly described the 
Hallmarks of Cancer, identifying the six abilities acquired by cancer cells that allow them 
to form tumors, induce angiogenesis, and metastasize [12].  Four of these six hallmarks 
pertain specifically to cell transformation:  sustaining proliferative signaling, resisting 
cell death, evading growth suppressors, and enabling replicative immortality.  More 
recently, Weinberg updated these hallmarks to include four new emerging hallmarks of 
cancer: dysregulating cellular energetics, avoiding immune destruction, genome 
instability and mutation, and tumor-promoting inflammation.  Genome instability and 
mutation influences the genetic changes that induce malignant cell transformation, and so 
they will be discussed within the context of the four hallmarks of transformation. 
Sustaining Proliferative Signaling 
Normal somatic cells receive external and internal signals throughout their normal 
lifespans that regulate proliferation.  During development, mitogenic stimuli signal 
differentiated cells to proliferate into a specified organ, and then proliferation ceases.  
Under normal conditions, homeostasis of the cells, and thus the organ itself is maintained 
via cell:cell signals, cell:basement membrane signals, as well as various paracrine and 
endocrine signals in the entire organism.  While much of the homeostatic cell:cell 
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signaling under normal conditions is not completely understood, proliferative signals in 
cancer progression are well studied.  The crux of the hallmark of sustaining proliferative 
signaling relies on the propagation of  cell signaling pathways that result in proliferation 
despite a lack of actual proliferative stimuli. 
Activation of mitogenic downstream signaling pathways; a focus on Ras 
Unrestrained proliferation can occur through multiple mechanisms; however, a 
common feature of hyper-proliferative cancer cells is the activation of downstream 
components of mitogenic signaling pathways.  A potent example is the classical 
oncogene, Ras.  Ras is the most frequently mutated gene in pancreatic cancer and its 
associated preneoplastic lesions; it is known to stimulate cell proliferation and contribute 
to the induction of pancreatic cancer [13]. 
Ras activation occurs in response to growth factor signaling.  Growth factors bind 
receptor tyrosine kinases, which become activated and recruit the guanine nucleotide 
exchange factor, SOS, to the plasma membrane where it facilitates the exchange of Ras-
bound GDP to GTP [14-16].  Binding of GTP induces a conformational change in Ras to 
its active state, allowing it to bind its potent downstream effectors at the plasma 
membrane where they are then activated.  The three main effectors in the Ras signaling 
pathway are PI3K, RalGEF, and Raf [17-19].  Stimulation of these pathways activates 
Akt signaling, Jnk/AP-1 transcriptional activity, and the MAP kinase cascade, 
respectively.  Ras-mediated activation of multiple cell signaling pathways is tightly 
regulated by GTPase activating protein, which stimulates the inherent GTPase activity of 
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Ras shortly after Ras becomes activated.  The resulting hydrolysis of GTP to GDP returns 
Ras to its inactive form, shutting off the signaling cascade [17,20].   
Normal human Ras is a protooncogene, which is a broad class of genes that 
control growth or proliferation and, if dysregulated, can cause cancer.  The most well 
studied mutation of Ras is a G12V mutation where glycine 12 is mutated to valine [21].  
This amino acid change ablates the GTPase activity of Ras, regardless of the presence of 
GTPase activating protein.  Loss of GTPase activity causes constitutive Ras activation, 
and thus continual stimulation of downstream proliferative signaling pathways, thereby 
effectuating its conversion from protooncogene to full-fledged oncogene.   
In addition to mutations in Ras itself, components of its downstream effector 
pathways may also be mutated to lead to excessively high levels of proliferative 
signaling.  Amplification of Akt has been documented in pancreatic, colon, breast, 
endometrial, and ovarian cancers [22].  Akt has a wide variety of targets that it 
phosphorylates including Mdm2, an inhibitor of p53; Raf, an upstream component of 
Map kinase signaling; and mTOR, a signaling protein responsible for angiogenesis as 
well as upregulation of cell cycle progression genes like c-Myc [23-26].  Akt can also 
phosphorylate targets to inhibit their activity, for example, Caspase-9, an apoptotic 
effector protein, and p21, an inhibitor of cell cycle progression [27,28].  The crucial 
element of the oncogenic activity resulting from activating mutations in, or amplification 
of, genes like Ras and Akt is the lack of dependence on growth factor signaling to induce 
activity.  In other words, the cell continually propagates signals to proliferate despite a 
lack of normal upstream proliferative stimuli. 
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Disruption of proliferation-regulating pathways 
In addition to over-activation of proliferative signaling, e.g. the activating G12V 
Ras mutation or amplification of Akt described above, loss-of-function of regulatory 
members of proliferative signaling pathways can lead to sustained proliferative signaling 
and induction of cancer.  These regulatory proteins are generally known as tumor 
suppressors due to their role in inhibiting cellular processes that, if left unchecked, can 
induce malignant cell transformation or contribute to cancer progression.  The tumor 
suppressor Phosphatase and Tensin Homolog (Pten) is a potent regulator of the PI3K/Akt 
activation pathway.  PI3K signaling is stimulated when Ras is activated [29].  After being 
recruited to the plasma membrane, it phosphorylates Phosphatidylinositol 4,5-
bisphosphate (PIP2) to form phosphatidylinositol (3,4,5)-trisphosphate (PIP3).  PIP3 
serves as a docking site for Phosphoinositide-dependent Kinase 1 (PDK1) which 
phosphorylates Akt on threonine 308 to serve as its initial activation step [30].  Pten is a 
phosphatase that dephosphorylates PIP3 to PIP2, blocking the recruitment of PDK1 to the 
plasma membrane and ultimately inhibiting the activation of Akt.  Pten mutations and 
loss of heterozygosity have been found in brain, prostate, breast, ovarian and pancreatic 
cancers [22].  Loss of this kind of regulatory mechanism also allows for inappropriate 
proliferative signaling.  
Senescence 
A natural barrier to malignant cell transformation is oncogene-induced 
senescence.  Senescent cells are characterized by lack of proliferation, lack of response to 
growth factors, and an enlarged, flattened morphology.  Induction of this phenotype can 
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occur in response to direct DNA damage or in response to oncogene activation [31].  
Cells with activated oncogenes stimulate proliferative downstream signaling that induces 
DNA replication at inappropriately high levels, which triggers a DNA damage response 
that signals the cell to undergo senescence [32].  When Ras is constitutively activated in 
cancer, its effector, Raf, initiates the Map kinase signaling cascade.  Map kinase signaling 
is potently mitogenic, and is particularly responsible for inappropriately high levels of 
DNA replication [33-35].  The prodigious number of replication forks during oncogene-
induced hyper-replication induces a DNA damage response through the ATM pathway, 
which ultimately up-regulates p53 activity [32,36].  The transcriptional target of p53, 
p21WAF1/CIP1, is induced when p53 levels are increased in response to DNA damage, and 
it inhibits the activity of Cyclin-Dependent Kinases (CDKs) which phosphorylate 
Retinoblastoma protein (Rb).  Phosphorylated Rb sequesters the transcription factor E2F, 
blocking its ability to promote progression through the cell cycle from G1 to S phase 
[37].  Other cell cycle arresting pathways converge, and ultimately, if the cell fails to 
repair the damage that initially induced the DNA damage response, the cell will 
permanently withdraw from the cell cycle and become senescent [37,38].   
 Senescence induction as a means of protection from oncogene activation is a first 
line of defense against allowing malignant cell transformation to occur, but it is also a 
dynamic process that continues throughout tumor formation [39].   By working to prevent 
the consecutive steps of cancer progression that lead to metastasis and death, senescence 





Resisting Cell Death 
Organized cell death, or apoptosis, is the process by which a cell systematically 
disassembles itself to be digested by surrounding cells and specialized phagocytes.  It is 
characterized by chromatin condensation and membrane blebbing, and is carried out by 
Caspase proteins.  Caspases are thiol proteases that are present in the cell as inactive pro-
caspases that are autolytically cleaved to form their active Caspase form in response to 
apoptotic signaling.  Once active, these proteases cleave structural proteins and other 
important cell components.  Apoptosis is necessary during normal development to 
eliminate extraneous cells.  For example, the cells between a developing mammal’s 
phalanges undergo apoptosis to allow for formation of individual digits.  Apoptosis is 
also important for the elimination of cells that pose a threat to the organism, e.g. cells 
with the potential to become cancerous.  Cells of this nature are typically cells that have 
excessive levels of DNA damage or mutations that either activate proto-oncogenes or 
down-regulate tumor suppressors.  
Apoptosis 
Apoptosis is exacted through two pathways: an intrinsic or mitochondrial pathway 
and an extrinsic pathway induced by death ligands binding to cell surface receptors. Both 
pathways ultimately result in the activation of effector Caspases, which are thiol 
proteases that cleave after aspartic acid residues. These apoptotic-specific proteases 
cleave structural proteins, signal transducers, regulators of transcription, repair factors, 
and many other targets within the cell. The apoptotic cell also prepares itself for 
phagocytosis by actively flipping phospholipids, specifically phosphatidyl serine, from 
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the inner to the outer leaflet of the cell membrane, creating a signal for phagocytosis of 
the disassembled cell by macrophages [41].   
 Genes upregulated by p53 in response to DNA damage include Puma and Noxa.  
These proteins are pro-apoptotic BH3 domain-containing Bcl-2 family members that 
exert their effects by antagonistically binding anti-apoptotic Bcl-2 family members, 
causing the release of BH123 family members such as Bax, another p53 transcriptional 
target.  Release of Bax allows for its oligomierization and translocation to the 
mitochondrial outer membrane, where it causes permeabilization of the outer membrane 
and release of Cytochrome C.  Cytochrome C is an important second messenger that 
binds and activates the adapter protein Apaf-1.  Apaf-1 binds procaspase 9 and forms 
aggregates, allowing for autolytic cleavage to the active form of Caspase 9.  Activation of 
Caspase 9 triggers a Caspase cascade that leads to activation of more Caspase proteins, 
which can then begin degrading structural proteins to prepare the cell for phagocytosis.  
This tightly regulated mechanism of cell death is necessary for maintenance of healthy 
tissue, and loss of this crucial process contributes to cell transformation and the 
persistence of cells with dangerous mutations. 
 Cancer cells frequently harbor dysregulated apoptotic machinery.  An example is 
the translocation of anti-apoptotic Bcl-2 to an immunoglobulin locus causing 
upregulation of Bcl-2 expression, and promotion of cell survival in follicular lymphoma 
[42].  In addition, p53 is mutated in nearly half of all cancers [43,44], and its loss of 




DNA Damage Response 
 DNA damage is caused by endogenous and exogenous insults to the cell.  
Endogenous causes of DNA damage include reactive oxygen species and replication fork 
collapse.  Exogenous sources of DNA damage range from radiation i.e. UV light, to 
chemical mutagens, to viruses.  DNA damage includes the formation or addition of bulky 
adducts such as the thymidine dimers caused by excessive UV light and breakage of 
DNA strands [45].  The most deleterious form of this is the double stranded break (DSB) 
[46]. 
When a cell acquires DNA damage, several mechanisms are activated to allow for 
repair.  The first signal relayed is that of the presence of DNA damage such as a DSB.  In 
response to this form of damage, normally supercoiled DNA relaxes [45].  This change in 
chromatin structure initiates the recruitment of Poly-ADP-ribose Polymerase (PARP) 
proteins and binding of kinases such as Ataxia-Telangiectasia Mutated (ATM) and DNA-
PK to the break site in order to modify histones.  Histone modifications include covalent 
linkage of Poly-ADP-ribose (PAR) chains by PARP proteins and phosphorylation of 
lysines by ATM and DNA-dependent protein kinase (DNA-PK).  The presence of PAR 
chains stops replication and transcription in the area of the DSB, and phosphorylated 
histones recruit DNA damage response proteins such as p53 and BRCA1 [47].  BRCA1 
is a well-studied tumor suppressor, recognized largely for its mutation in familial breast 
cancer [48].  The transcription factor and tumor suppressor p53 has long been known as 
the guardian of the genome. Its functions are well studied and include transcriptional 
upregulation of proapoptotic genes [49]. p53 is maintained at low basal levels in the cell 
by its inhibitory protein, Mdm2, which inhibits p53 function by acting as an ubiquitin 
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ligase to target p53 for proteasomal degradation as well as by binding to and blocking the 
DNA binding domain of p53, inhibiting its activity as a transcription factor [50]. Upon 
detection of DNA damage, DNA-PK and ATM bind the DSB and phosphorylate histone 
H2AX [51].  This DSB-detection signal recruits p53, which is then phosphorylated on its 
N-terminus at serine 15 by DNA-PK or ATM.   Phosphorylation at this site blocks 
inhibition by Mdm2 and promotes binding to p53 response elements in the promoter 
regions of proapoptotic genes [41,52,53]. 
Other signal cascades involve activation of cell cycle check point proteins and 
DNA repair enzymes to arrest the cell cycle to allow time for appropriate repair of 
damaged DNA.  Repair of DSBs can occur through two pathways: Homologous repair 
(HR), and Non-homologous end joining (NHEJ).  NHEJ frequently introduces errors, and 
in the case of multiple DSBs, may lead to fusion of nonhomologous chromosomes.  Once 
the cell repairs a DSB, the checkpoint machinery is deactivated, and the cell is once again 
allowed to progress through the cell cycle [54].  Newly introduced errors that were not 
corrected become mutations that can have deleterious effects such as deactivation of 
tumor suppressors like p53 and other pro-apoptotic genes, up-regulation of oncogenes, 
and other gross changes to the cell’s morphology and metabolism. 
Oncogene Activation 
Propagation of genetic errors such as point mutations, gene amplifications, and 
chromosomal translocations can lead to disruptions in gene expression and/or gene 
function.  A potent example is the proto-oncogene Myc, which is the most frequently 
amplified oncogene in human cancers and whose translocation was first discovered as the 
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driving force in Burkitt Lymphoma [55-57].  Myc is a tightly regulated transcription 
factor whose target genes include ODC and Gadd45α, both of which are implicated in c-
Myc driven proliferation [58].  Low levels of Myc activity are tolerated in the cell and act 
as a signal to grow and proliferate; however, high levels of Myc activity trigger activity 
of Arf, a tumor suppressor that induces cell cycle arrest via p53 and can ultimately lead to 
apoptosis [59,60].  In this way, the strongly oncogenic signaling of Myc is quelled before 
out of control proliferation occurs.  Other proto-oncogenes also induce apoptosis as a 
safety mechanism if their signaling or activity becomes abnormally high. 
 Overall, loss of the apoptotic response allows cells to acquire and propagate 
mutations that would normally induce the DNA damage response pathway and lead to 
apoptosis.  Propagated mutations that activate oncogenes result in unrestrained 
proliferation or growth, which are normally controlled by feedback mechanisms that 
detect such inappropriate signaling levels and induce apoptosis.  Loss of apoptotic 
pathway components then results in unimpeded cell survival. 
Evading Growth Suppressors 
 As established earlier, malignant cell transformation depends on loss of tumor 
suppressors that induce apoptosis, arrest the cell cycle, or regulate proliferative signaling.  
These include p53, Rb, and Pten, respectively, demonstrating the significant overlap of 
Weinberg’s Hallmarks of Cancer within the malignant cell transformation.  Impediments 
to unrestricted cell survival and proliferation are frequently lost or mutated in cancer, and 
their mechanisms are well studied; however, more intricate processes of cell growth 





 Non-transformed cells, when grown in culture, will experience a slowing of 
proliferation as they reach confluence.  This phenomenon was first discovered in the 
1960s when cells were first being experimentally cultured in laboratories, and was termed 
the Hayflick phenomenon.  It has recently been studied more extensively, however it is 
not completely understood, and its relevance in vivo is not completely established [31].  
What has been deduced is that cells, particularly epithelial cells, experience growth 
inhibition with respect to adjacent cells.  The cell signaling pathways responsible for this 
are not fully known, but it has been shown under various conditions and with multiple 
cell types that non-transformed cells will grow into a single-layered sheet of cells in vitro, 
mimicking the single epithelial layer seen in vivo such as in the intestinal wall or luminal 
mammary gland ducts [12].  The physical touching of the cells relays signals, most likely 
through cell:cell junctions and extracellular structural proteins, that inhibit proliferation.  
A distinct feature of transformed cells is their ability to proliferate despite the growth 
inhibitory signals being relayed by their contact with other cells.  The result of avoiding 
these particular growth suppressing signals is a mound of cells that are continuously 
proliferating, or, in vivo, a tumor.   
 A second form of growth control occurs when cells lose cell:basement membrane 
contacts.  This specific form of apoptosis is called anoikis, and is responsible for the 
organized cell death of cells that lose such crucial structural contacts [61].  A hallmark of 
cancer cells is their ability to either escape the constraints of normal tissue structures, or 
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to degrade and invade the basement membrane.  This invasive and migratory ability is 
coupled to the ability to evade the growth-suppressing signals that would induce anoikis 
in response to loss of these structural contacts [62].   
Enabling Replicative Immortality 
Telomeres 
Telomeres are protein-DNA complexes that protect the ends of linear 
chromosomes from being targeted by DNA damage-repair machinery.  They consist of a 
double stranded (DS) stretch of tandem TTAGGG repeats that terminates in a single 
stranded (SS) G-rich 3’ overhang.  Telomere associated proteins such as the Shelterin 
complex coat this SS region to prevent its recognition as DNA damage.  Telomeric 
proteins also aid in the formation of complex structures such as G-quadruplexes and T-
loops that cap the end of the chromosome, further disguising the chromosome end from 
being recognized as DNA damage [63].  Replication of telomeres is a complex and 
important process.  Coordinating the removal of this plethora of proteins with 
dismantling the complex structures within the telomere is a finely tuned process that 
serves to maintain the delicate balance between a healthy cell and a prematurely 
senescing cell.  Replication also poses a significant challenge to telomeres because with 
each round of replication, DNA on the end of the chromosome is lost, due to the inability 
of the replication machinery to replace RNA primers with DNA on the lagging strand.  
Aberrant replication can lead to fork pausing and unreplicated telomeres which cause 
premature senescence and cell death.  Loss of telomere-associated proteins can lead to 
severe physiological defects such as the premature aging seen in Werner syndrome.  The 
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leading strand of the telomere, however, does not experience this shortening due to 
Okazaki fragmentation.  Instead, DNA polymerase replicates off the end of the telomere, 
leaving behind a blunt end in need of resectioning by an endonuclease to form the 
classical 3’ overhang necessary for proper telomere function.  Several reports suggest that 
this nucleolytic activity is performed by Apollo, a nuclease found both at telomeres and 
double stranded breaks (DSBs).  The function of Apollo requires stimulation by the 
multifunctional protein, Trf2.   
Trf2 is a conserved telomeric protein with a wide repertoire of functions.  It is a 
member of the Shelterin complex that helps disguise the telomere from being recognized 
as DNA damage, and it functions in the formation and stabilization of the t-loop that 
buries the single stranded 3’ overhang within the double stranded portion of the telomere.  
Trf2 also recruits Apollo [64], whose endonuclease activity is stimulated by Trf2 both to 
relieve topological stress during replication [65] and to resection the blunt end of the 
leading strand telomere into a 3’ overhang directly following replication [66,67].  
Notably, Apollo’s interaction with Trf2 at this significant structure is necessary to 
prevent major telomere dysfunction [67]. Trf2 has also been recently implicated by 
various sources in the recognition and repair of DSBs in response to various forms of 
damaging radiation [68-70].  Trf2 is rapidly phosphorylated in response to DSBs. This 
phosphorylation has proved necessary for both the transient recruitment of Trf2 to these 
DSBs and the initiation of DNA repair [70].  Interestingly, in times of telomere crisis, or 
during the alternative lengthening of telomeres (ALT) pathway, phosphorylated Trf2 has 
been shown to localize to the telomere [70].  This discovery is not unexpected because 
many DNA damage-related proteins and telomeric proteins have been found to function 
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within both contexts [69,71,72].  Apollo is also recruited to DSBs and interacts with 
ATM [73], a crucial signal transducer in the DNA damage recognition pathway that leads 
to non-homologous end joining (NHEJ). Trf2 is proposed to hold ATM inactive at 
telomeres and DSBs.  Although controversial, it has been shown that ATM may mediate 
phosphorylation of Trf2 in response to DNA damage [68,70,74].   
The presence of the telomere protects important genomic DNA from this loss, but 
overall, this shortening of telomeres is part of the aging of the cell and eventually results 
in naturally occurring senescence.  With each round of cell division, a cell must replicate 
its DNA before separating into daughter cells.  The DNA polymerase enzyme responsible 
for replicating the genome is not able to fully replicate the ends of eukaryotic linear 
chromosomes, and so with each round of cell division, small amounts of DNA remain un-
replicated and are lost.  The ends of chromosomes thus are comprised of several 
kilobases of telomeric G-rich repetitive sequence.  Cells are protected from the loss of 
valuable genomic coding sequence DNA by telomeres because the repetitive telomeric 
sequences do not contain genes, and telomere shortening during cell division serves as an 
internal clock that senses when the telomeres have become too short for safe replication 
and stops the cell from replicating.  Because of the “internal clock” function of telomeres, 
they are thought to play an integral role in the aging process.  It is notable that the 
proteins required for maintenance of the cell’s “internal clock” also function within the 
DNA repair pathway, highlighting the complexity and overlap of Weinberg’s defined 
hallmarks. 
An enzyme complex called Telomerase is specifically required for synthesis of 
telomeric sequence, and in normal cells, this enzyme is not fully expressed.  Telomerase 
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is comprised, minimally, of two subunits: TERT, a reverse transcriptase enzyme, and 
TER, a large RNA subunit.  A portion of TER contains the sequence specific template 
utilized by TERT for adding nucleotides to uncapped telomeres.  This sequence is small, 
compared to the rest of the RNA strand, which is large, and whose sequence is largely 
divergent between species.  Phylogenetic studies have, however, determined the 
conserved secondary structure of this RNA subunit, which has been determined to assist 
in the protein interactions required for Telomerase holoenzyme recruitment to the 
telomere, as well as further recruitment of other interacting proteins.  In vitro, these two 
subunits are all that are required for Telomerase reverse transcriptional activity; however, 
in vivo, other interacting proteins, such as RNA binding proteins and DNA binding 
proteins involved in recruitment and stabilization of the Telomerase:telomere interaction, 
are necessary for the enzyme’s functionality.  Telomerase is, in general, not active or 
expressed in adult somatic cells; however, certain cell types such as highly proliferative 
germ line cells, smooth muscle cells, and certain lymphocytes, retain Telomerase 
functionality.  In these cells, Telomerase activity and telomere length are maintained by a 
phenotypic switch between capped and uncapped states of the telomere.  As telomeres are 
replicated, they become progressively shorter; however, telomere binding proteins such 
as Apollo, Trf2, and other members of the Shelterin complex vivaciously coat the 
telomere and help induce the secondary structures that telomeres form, e.g. T-loops.  The 
coating action of telomere-associated proteins complements the telomeric DNA 
secondary structures, forming a protective cap on the chromosome’s end.  This cap 
prevents recognition of the DNA ends as DSBs, but also regulates Telomerase activity.  
Capped chromosomes are less likely to be extended by Telomerase, however, as 
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replicating cells’ telomeres are progressively shortened, they are less likely, and less able 
to form protective caps, allowing for extension by Telomerase.  By switching between 
two forms—capped and uncapped—telomeres are maintained within upper and lower 
length limits in Telomerase-positive cells.  This regulation is crucial to avoid hyper-
extension of telomeres as well as recognition of telomeres as DSBs, both of which are 
implicated in cancer.  
Studies have shown that Telomerase is frequently reactivated in human cancer by 
various mechanisms.  Some reports show that Myc hyper-activation can induce TERT 
expression, and it is one of the genetic changes found necessary by Weinberg’s lab for 
oncogene cooperation-induced malignant cell transformation of human cells.  Another 
important mechanism of Telomerase reactivation in cancer cells is the re-activation of a 
telomere maintenance program in order to bypass telomere damage-induced crisis and 
senescence.  Rapidly dividing cells frequently incur DNA damage due to the plethora of 
replication forks that overwhelm the cell.  Even more problematic during replication is 
the process of dismantling the precarious secondary structures and intricate protein-DNA 
complexes that cap the ends of the chromosomes.  This process can pose problems during 
normal replication, but during the rapid proliferation seen in cancer, this invariably leads 
to damaged chromosomes.  These telomere damage-induced foci (TIF) trigger a p53 and 
Rb dependent DNA damage response, but the massive influx of DNA damage typically 
overwhelms the cell and induces crisis.  Crisis is comprised of misguided attempts by the 
DNA repair machinery to repair the linear ends of chromosomes, having recognized them 
as DSB.  The end result is more damage as telomeres become fused and chromosomes 
break.  This cycle overwhelms the cell and eventually causes senescence.  In the absence 
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of p53 activity or intact DNA damage response pathways, or perhaps even due to the loss 
of such pathways during crisis, a cell will survive crisis and propagate its gross genetic 
damage as mutations.  A crucial component of this is the re-activation of telomere 
maintenance machinery.  This almost always involves the re-expression of TERT.  The 
mechanisms of Telomerase reactivation are not fully known, but promoter mutations 
have been found in many cancers, including thyroid, central nervous system and skin 
cancers, glioblastoma, and over half of bladder cancers [75].  By establishing a telomere 
maintenance program, the cell is able to avoid normal cellular lifespan limits, i.e. achieve 
immortality.  Immortality is one of the first steps in malignant cell transformation, and 
expressing Telomerase is crucial in this immortalization process.  However, primary 
mouse embryonic fibroblasts MEFs, which express Telomerase, will not grow 
indefinitely in culture; p53KO MEFs will, indicating that while Telomerase function is 
involved in malignant cell transformation, it is a component of a complex, dastardly 
process.  It is notable that rodents constitutively express Telomerase, making their cells 
easier to indefinitely culture in vitro, but presenting a major difference when studying 
malignant cell transformation in rodent models.  
Oncogene Cooperation 
Weinberg’s hallmarks of cancer indicate the multiple processes that occur in 
cancer, or, with respect to the specific four described above, malignant cell 
transformation.  In molecular biology terms, the requirement of multiple processes to 
induce cell transformation translates to changes in cell signaling pathways, either by up-
regulation of proto-oncogene activity, or loss of either function or expression of tumor 
suppressors.  Although certain proteins, for example Ras, can activate multiple 
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downstream effector pathways, multiple genetic changes are required for cell 
transformation.   
Historically this was attributed to viral oncogenes that stimulated Telomerase 
activity, inhibited apoptotic and senescence-inducing machinery, and stimulated 
proliferation [76-78].  However, Weinberg’s landmark paper in 1983 demonstrated the 
requirement of two oncogenic hits to transform primary fibroblasts, and in so doing, 
described for the first time the synergistic effect of Ras and Myc signaling to induce cell 
proliferation without triggering apoptosis or senescence, which occurs when each 
oncogene is over-expressed individually [79].  Cooperation of Ras and Myc coselects for 
loss of p53 function.  Dysregulation of Ras and c-Myc signaling delineates a classical 
paradigm of oncogene cooperation, and continued activation of both of these pathways 
allows cells to bypass senescence, escape apoptosis, and enter into a malignant, 
hyperproliferative state [79,80].   
In 2005, Boehm et al. delineated the nonviral genes necessary for human cell 
transformation [81].  While Ras and c-Myc transform primary rodent cells, which express 
Telomerase, human cells maintain more stringent checkpoints and require reactivation of 
Telomerase, as well as loss of function of tumor suppressors.  The specific changes in 
human cellular pathways originally identified are activation of Ras, Myc, and TERT, 
along with the loss of function of p53, Retinoblastoma protein, and PTEN [81].  All of 
these combine to allow replicative immortality, hyperproliferation, and deactivation of 
cell cycle checkpoints that would not under normal circumstances allow propagation of 
genetic mutations that drive cell transformation [81-83].  The specific mutations 
necessary to transform human cells is more complicated than in rodent cells, but the 
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ultimate result for both is the survival of cells that are no longer governed by pathways 




MicroRNAs (miRNAs) are an abundant class of regulatory noncoding RNAs that 
regulate thousands of genes across a vast array of signaling networks and cellular 
functions [84].  The first miRNAs discovered were lin-4 and let-7 in C. Elegans [85,86].  
These miRNAs were found to be expressed temporally and play crucial roles in 
development.  The field expanded to the cornucopia of small regulatory RNAs that it is 
today with over 2500 mature miRNAs identified in humans alone.  As research 
progresses, it has become clear that miRNAs are key regulators in all major cellular 
processes. 
Genomic Location and Biogenesis 
 miRNAs are present in introns within coding or non-coding transcribed units, or 
as exons, i.e. independent genes.  miRNAs may be present as single autonomous miRNA 
genes; however, over half of human miRNAs are present as miRNA clusters that are co-
expressed as polycistronic units [87].  Members of miRNA clusters frequently target 
similar or related genes, culminating in an increased overall effect on a single pathway or 
protein complex, rather than broad, unrelated targeting by multiple miRNAs [88-91].  
Many miRNA clusters occur because of gene amplifications or insertions, resulting in 
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multiple copies of identical or similar sequences [92,93].  This in turn results in nearly 
identical targeting patterns.  Similarly, related mRNAs harboring binding sites 
corresponding to the same miRNA or miRNAs indicates a coordinated mechanism of 
gene regulation [94]. 
The majority of miRNAs are processed from introns of mRNA.  Experimental 
evidence shows that processing of miRNAs need not occur only after splicing out of the 
intron, and that miRNA processing does not affect mature mRNA assembly [95].  
Intronic and Exonic miRNAs are transcribed by RNA Polymerase II, and exonic 
miRNAs are processed similarly to mRNA, in that they are capped with 5’meG and 
polyadenylated.  After miRNAs are transcribed, intra-strand regions of complementarity 
result in the formation of an imperfect hairpin loop (pri-miRNA). The functional miRNA 
sequence is present on the arm of this loop [87].  The biogenesis of this primary transcript 
is what differentiates miRNAs from other small interfering RNA within the RNA-
mediated gene silencing field.  Rather than cleavage into multiple small regulatory 
molecules, pri-miRNAs are “cropped” in the nucleus into small hairpin structures called 
pre-miRNAs. This cropping enzyme is known as the microprocessor, and is comprised of 
the class II Ribonuclease III enzyme, Drosha, and DGCR8, a double stranded RNA 
binding protein [96].  Cropping by the microprocessor complex is the initiating event of 
miRNA processing, as loss of these enzymes leads to accumulation of pri-miRNAs and 
reduced pre-miRNA levels.  Following microprocessor cropping, pre-miRNAs are 
exported to the cytoplasm via Exportin5/RanGTP [97].  Exportin5 is a nuclear transporter 
that exports pre-miRNAs in complex with RanGTP.  The entire complex is shuttled 
across the nuclear membrane to the cytoplasm where RanGAP stimulates hydrolysis of 
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GTP to GDP, and the pre-miRNA is released into the cytoplasm [98].  Once in the 
cytoplasm, they are cleaved by the class I Ribonuclease III, Dicer, to form imperfect 
duplexes.  The 3’ overhang of pri-miRNA is recognized by the PAZ domain of Dicer, 
and its catalytic RNAse III subunit cleaves the stem loop into a ~22 nt miRNA duplex.  
In general, the strand with the least stable 3’ end base pairing functions as the guide 
strand while the other strand, often annotated miR*, is degraded.  However, both the 
canonical guide strand as well as the star strand of several miRNAs have been shown to 
be functional.   
Mechanism 
To effect gene silencing, the guide strand is loaded into the RNA-induced 
silencing complex (RISC), which binds target mRNA 3’ Untranslated regions (UTRs) in 
a miRNA seed sequence-directed manner [84].  The RISC is a large enzyme complex 
whose major functional unit is Argonaute (Ago2).  Ago2 is a versatile enzyme involved 
in RNA-induced silencing.  Perfect complementarity between the silencing RNA and the 
mRNA directs mRNA strand cleavage.  This is always the case with siRNA, and 
occasionally with miRNA-mediated silencing.  The mechanism of gene silencing 
employed by miRNAs, however, revolves around translational repression, in which Ago2 
does not cleave target mRNA [84,99].  Indeed, most miRNA targets are not based on 
perfect base pairing; however, the perfect base pairing dictating mRNA cleavage is not a 
hard and fast rule.  Ago2 has recently been found to associate with P-bodies, and one 
potential mechanism of gene silencing may involve sequestering of RISC-associated 
mRNA in P-bodies to down-regulate protein expression [99].   
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The Argonaute complex is targeted to specific mRNA by base pairing between 
the miRNA and the 3’ UTR of the target mRNA [84].  Nucleotides 2-7 on the 5’ end of 
the miRNA are known as the seed sequence.  Complementarity between these bases and 
target mRNA 3’UTRs results in the specific targeting and regulation of those mRNA.  
Complementarity is rarely perfect, and binding sites vary in their affinities based on 
sequence complementarity, as well as the presence of an Adenosine within the mRNA 
UTR in line with the first nucleotide of the miRNA.  Canonical sites include the 7mer-
A1, in which there is perfect complementarity between the miRNA seed sequence and the 
mRNA, as well as an mRNA adenosine at the first nucleotide position; the 7mer-m8 site, 
in which there is perfect base pairing within the seven nucleotides of the seed sequence, 
as well as at the 8th nucleotide position, which is not included as part of the canonical 
seed sequence; and the 8mer site, in which there is perfect complementarity between the 
seed sequence and the 8th nucleotide, as well as an mRNA adenosine at position 1.  
Marginal binding sites are 6mers, in which there is complementarity between the miRNA 
seed sequence and the target mRNA, but no compensatory adenosine at position 1, and 
no match at the 8th nucleotide.  Similarly, other 6mers include complementarity at six 
contiguous bases that occur only partially within the seed sequence.  Targeting is also 
enhanced by compensatory complementarity that occurs several bases downstream of the 
seed sequence site.  This particularly enhances targeting when seed sequence 
complementarity contains one or more mismatched bases.  Canonical and marginal 








Table 1.  Canonical and Marginal miRNA binding sites. Lower strand: miRNA 
Upper Strand: target mRNA.  ORF: Open reading frame, N: complementary 
nucleotide, NNNNNN: seed sequence, A: position 1 adenosine. 
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MicroRNAs in Cancer 
Because of their regulation of such crucial cell signaling pathways, dysregulation 
of miRNAs contributes to disease, for example cancer [100].  Just as protein coding 
genes become dysregulated in cancer [82,101], miRNA genes may also become 
aberrantly over expressed or silenced [100,102].  miRNAs within introns are subject to 
regulation by changes in the promoter controlling the host gene [95].  Other miRNAs 
expressed from the genome as independent transcripts may be epigenetically modified at 
their promoters to affect expression levels [100,103-107]. miRNAs are also subject to 
gene amplification and deletions [108,109]. 
By targeting one or more tumor suppressors, miRNAs can function as oncogenic 
miRNAs (oncomiRs) when aberrantly over-expressed.   miR-21 has emerged as a 
canonical example of an oncomiR.  miR-21 is up-regulated in nearly all epithelial cell-
derived solid tumors including breast, pancreas, lung, gastric, prostate, colon, head and 
neck, and esophageal cancers.  It is also reported to be up-regulated in hematological 
malignancies such as leukemia, lymphoma and multiple myeloma.  miR-21 is over-
expressed in glioblastoma, osteosarcoma, and spermatocytic seminoma.  Thus, miR-21 is, 
as yet, the only gene that is found to be overexpressed in all major classes of human 
cancers derived from epithelial cells, connective tissues, hematopoietic cells, or nervous 
cells.  Its target genes include regulators of apoptosis, cell cycle progression, growth 
factor signaling, and proliferation [41].  It has been found to directly target such well 
known tumor suppressors as Pten and Bcl2.  miR-21 overexpression in MCF-7 human 
breast cancer cells promotes colony formation by directly targeting the tumor suppressor 
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PDCD4 and suppressing its expression [110].  The role of miR-21 in cancer exemplifies 
the diverse targeting and dastardly effects of oncomiRs. 
In addition to dysregulation of single exonic miRNA genes, entire miRNA 
clusters may be dysregulated in cancer, for example the miR-17~92 cluster is frequently 
up-regulated in cancer, specifically, its genomic locus is amplified in diffuse large B-cell 
lymphoma [108].  It contains several homologous miRNAs that target pro-apoptotic 
genes such as p21 and Bim [100].  Dysregulation of this coordinated targeting of major 
cell signaling regulators contributes strongly to the progression of cancer.  Overall, the 
over-expression of oncogenic miRNAs leads to both the targeting and loss of tumor 
suppressive mechanisms.   
In contrast, miRNAs may function as tumor suppressors by targeting oncogenes 
and regulating their expression.  Tumor suppressor miRNAs are often down-regulated in 
cancer [100,102].  The let-7 family is a well-studied tumor suppressor miRNA family 
comprised of 12 miRNA family members.  These family members have been found to 
target and regulate expression of the proto-oncogenes Ras and Myc, as well as other 
oncogenic proteins such as CDK6 and Cyclin D, cementing its role as a tumor suppressor 
by regulating proliferation and crucial cell cycle promoting enzymes [100].  Expression 
of the let-7 miRNA family is frequently down-regulated in human lung cancer cases, 
which also exhibit higher levels of Ras expression [111].  This is in contrast to cancers 
that express mutated, constitutively active forms of Ras, strongly implicating 
involvement of let-7 family dysregulation in cancer pathogenesis.  Similarly, in 31-64% 
of medulloblastomas, the most common central nervous system tumor in children, Myc is 
over-expressed; however, the Myc gene is amplified in only 5-8% of medulloblastoma 
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cases.  The locus containing miR-33b is frequently lost in medulloblastoma, and miR-33b 
has been shown to directly target Myc and repress its expression in medulloblastoma cell 
lines [112].  These studies provide evidence for the involvement of miRNAs in regulation 
of proto-oncogenes, indicating their importance in homeostasis and, in turn, the role their 












Figure 1.   The miR-200 family 
Figure 1.  The miR-200 family Upper: Genomic organization of miR-200 family.  





miR-200a is a member of the miR-200 family.  This family is comprised of five 
members present in the genome as two clusters (Figure 1).  The first cluster is located on 
chromosome 1 at locus 1p36.33 and contains miR-200b, miR-200a, and miR-429.  The 
second cluster is located on chromosome 12 at locus 12p13.31 and contains miR-200c 
and miR-141.  miR-200a and miR-141 contain identical seed-region sequences of 
AACACUG, and miR-200b, miR-200c, and miR-429 contain identical seed sequences 
that differ from the other seed sequence by one nucleotide: AAUACUG.  Because of 
these shared seed sequences, miR-200a and miR-141 are predicted by targeting 
prediction algorithms to regulate the same genes.  While the entire family is frequently 
expressed together and demonstrated to regulate the same targets [113], both clusters do 
not always have identical functions [114]. 
Along with its family members, the first and most well studied function of miR-
200a is in maintenance of epithelial cell morphology through regulation of the pro-
mesenchymal Zeb transcription factors [115,116].  Zeb1 and Zeb2 directly bind the 
promoter of the epithelial marker E-cadherin to down-regulate its transcription.  
Likewise, Zeb1/2 directly bind the promoter and stimulate transcription of the 
mesenchymal marker Vimentin.  By regulating these pivotal transcription factors, miR-
200a promotes epithelial cell morphology, and inhibits the epithelial-mesenchymal 
transition (EMT).  EMT is the critical initiating step of metastasis and as such, is crucial 
in the progression from primary tumor to deadly metastasis [117].  As a potent regulator 
of this process, miR-200a is frequently an inhibitor of metastasis, and thus functions as a 
tumor suppressor [118,119].  Several studies in cancer cell lines and tumor samples 
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demonstrate the down-regulation of miR-200a in mesenchymal metastatic cells 
[105,120,121].   
Conversely, emerging studies show cancer cell populations and tumor samples 
that over-express miR-200a and rely on its over-expression for metastatic colonization, 
growth, and survival [5,62,122,123].  Many of these studies remain focused on EMT and 
suppose that maintenance of an epithelial-like morphology by the miR-200 family either 
accounts for heterogeneity of tumor cells [124], or promotes a reversal of EMT, allowing 
for metastatic colonization at sites distant from the primary tumor [123].  A study in an 
isogenic series of  breast cancer cell lines with increasing invasiveness and metastatic 
potential, demonstrated that the cell line that is able to fully invade, metastasize and 
colonize distant organs from the primary tumor site is the only cell line in the series that 
expresses the miR-200a family.  Targeting of Sec23 by the miR-200 family was 
demonstrated to affect the cells’ secretome and regulate the ability of these cells to 
invade.  The authors concluded that the miR-200a family promotes the ability to colonize 
distal sites during metastasis, a novel role for the miRNA family often regarded as a 
tumor suppressor.  The authors speculated that promotion of an epithelial phenotype is 
necessary for establishing metastatic tumors.  Another breast cancer cell line study 
demonstrated that an enhancer specific to the miR-200b~429 cluster, which also includes 
miR-200a, is responsible for high expression levels of miR-200a in epithelial breast 
cancer cells [107]. 
In pancreatic cancer cells, miR-200a has been shown to be hypomethylated and 
differentially over-expressed, along with its family member miR-200b [105].  
Meanwhile, its canonical target, Zeb1, was found to be hypermethylated and silenced, 
32 
 
indicating that the consequences of miR-200a overexpression in this pancreatic cancer 
model were occurring separately from its role in EMT inhibition via Zeb1 repression.  
miR-200a and miR-200b were also found at higher levels in the sera of pancreatic cancer 
patients, highlighting the importance of this miRNA in a clinical disease setting, as well 
as the potential use of miR-200a and its family members as biomarkers in disease. 
A miRNA expression analysis study revealed that miR-200a was expressed at 
levels higher in epithelial ovarian cancer samples than in benign cysts.  Further 
stratification revealed that miR-200a expression was associated with early stage tumors, 
and that late stage metastatic tumors expressed significantly lower levels of both miR-
200a and E-Cadherin [125].  Overexpression of miR-200a in earlier stages of cancer, 
rather than the metastatic steps associated with a mesenchymal phenotype, is consistent 
with both the established role of miR-200a in promoting an epithelial phenotype as well 
as the newer studies that demonstrate a role for miR-200a in proliferation and growth. 
Another novel target of miR-200a is Yap1, a key mediator in the Hippo signaling 
pathway, and a known regulator of anoikis [62].  miR-200a was found to directly target 
Yap1 in breast cancer cells, and overexpression of miR-200a resulted in anoikis 
resistance of human breast cancer cells in animal models.  By targeting such a crucial 
regulator of cell homeostasis, miR-200a was able to enhance metastatic potential of these 
breast cancer cells. 
 miR-200a has also been shown to up-regulate PI3K signaling and Akt activity by 
targeting Fog2, which binds and inhibits the regulatory subunit of PI3K [102].  This study 
demonstrates a role for miR-200a in promoting cellular growth, unrelated to its role in 
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maintenance of an epithelial phenotype.  miR-200a has a dichotomous role in the 
promotion and inhibition of different metastatic steps, and has an emerging role in 
cellular growth and survival.   
Hypothesis and Research Strategy 
Taken together, it is clear that miRNAs play crucial roles in cancer progression 
and are frequently dysregulated during all stages of oncogenesis.  It is crucial to study the 
molecular events that occur early in cancer progression in order to enhance detection and 
diagnostic techniques as well as to aid in cancer prevention.  To characterize specific 
miRNA roles in cancer initiation, the following hypothesis was proposed: 
MicroRNAs function as oncogenes in malignant cell transformation. 
In this study, a biphasic approach was employed to characterize the role of 
miRNAs in cancer initiation.  We first examined the role of miRNAs grouped according 
to genomic cluster in four major cancer signaling pathways: AP-1, NF-κB, c-Myc, and 
p53.  Our second step was to screen miRNAs for the ability to transform epithelial cells.   
In our first step, we found that miR-200a directly suppresses p53 and inhibits 
apoptosis.   In the second step, we found that miR-200a transforms immortalized rat 
epithelial RK3E cells, and, when expressed with Ras, miR-200a enhances transformation 
of immortalized human epithelial MCF10A cells.  Further characterization of the 
mechanism behind miR-200a’s ability to transform cells revealed that miR-200a 
cooperates with the RalGEF effector pathway of Ras to transform MCF10A cells and 
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A SYSTEMATIC SCREEN REVEALS MICRORNA CLUSTERS THAT 
SIGNIFICANTLY REGULATE FOUR MAJOR SIGNALING PATHWAYS. 
Chapter Overview 
MicroRNAs (miRNAs) are encoded in the genome as individual miRNA genes or 
as gene clusters transcribed as polycistronic units. About 50% of all miRNAs are 
estimated to be co-expressed with neighboring miRNAs. Recent studies have begun to 
illuminate the importance of the clustering of miRNAs from an evolutionary, as well as a 
functional standpoint. Many miRNA clusters coordinately regulate multiple members of 
cellular signaling pathways or protein interaction networks. This cooperative method of 
targeting could produce effects on an overall process that are much more dramatic than 
the smaller effects often associated with regulation by an individual miRNA. In this 
study, we screened 366 human miRNA minigenes to determine their effects on the major 
signaling pathways culminating in AP-1, NF-κB, c-Myc, or p53 transcriptional activity. 
By stratifying these data into miRNA clusters, this systematic screen provides 
experimental evidence for the combined effects of clustered miRNAs on these signaling 
pathways. We also verify p53 as a direct target of miR-200a. This study is the first to 






MicroRNAs (miRNAs) are small RNA molecules 20-25 nucleotides in length.  
Through complementary base pairing, miRNAs bind the 3' UTR of target mRNAs to 
post-transcriptionally down-regulate gene expression.  Originally discovered in C. 
elegans, the first miRNA was found to be a key regulator of development [87,126]; 
however, subsequent studies have revealed a myriad of roles for miRNAs in virtually all 
biological processes.  Studies highlighting the biological function of miRNAs have 
emerged alongside studies that reveal the detrimental effects of miRNA dysregulation 
[127].  Many miRNAs, when lost or over-expressed, become crucial players in the 
oncogenic process [128,129].  miRNAs may target a wide variety of genes, including 
those most closely associated with the processes of cancer development, particularly the 
hallmarks of cancer [41,82].  By inhibiting expression of tumor suppressors, miRNAs 
may function as oncogenes.  Conversely, miRNAs can also exhibit tumor suppressive 
properties by repressing oncogenes. 
miRNAs are transcribed and processed from intronic or intergenic regions, and 
may be transcribed as individual miRNA or as polycistronic transcripts (clusters) [87,95].  
Primary miRNA transcripts (pri-miRNA) are processed into imperfect stem-loop 
structures called pre-miRNAs by Drosha in the nucleus and then exported into the 
cytoplasm by Exportin V.  These pre-miRNAs are cleaved by Dicer to form mature 
miRNAs, which are then incorporated into the RNA-induced silencing complex (RISC).  
Imperfect complementary base-pairing between the miRNA and mRNA directs the RISC 
to the 3’ UTR of target mRNA.  This targeting leads to down-regulation of translation of 
the mRNA, and is often accompanied by a decrease in mRNA levels  [87]. 
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Nearly half of all miRNA genes are within 50 kilobases of another miRNA gene 
[88].  These clusters range from 2 miRNAs, for example miR-200c and miR-141, to as 
many as 46 miRNAs, as seen in the largest miRNA cluster in primates, Chromosome 19 
miRNA Cluster (C19MC) [88,130,131].  miRNAs within clusters frequently contain high 
sequence homology, particularly within the seed sequence, resulting in identical targets 
[5,123].  Recent evidence, however, points to clustered miRNAs that target different 
genes within a specific pathway or protein complex [89,132].  miRNAs are also predicted 
to target downstream effectors of cellular signaling pathways such as second messengers 
and transcription factors (TFs) more frequently than upstream ligands and receptors or 
housekeeping and structural genes [133].  TFs are key players in cell signaling pathways.  
By responding to a plethora of extra- or intra-cellular stimuli and regulating transcription 
of the many genes necessary for a cellular response, TFs act as crucial cell signaling 
hubs.  Dysregulation of major TFs is often a key event in oncogenesis [134].  Such TFs 
include AP-1, NF-κB, c-Myc, and p53 [57,135-137].  Many individual miRNAs target 
these pathways [138-141], but little data exists regarding the full effect of miRNA 
clusters.  While it is clear that miRNA clusters are frequently predicted to target specific 
cell signaling pathways, no experimental evidence based on systematic screening has 
been provided.  In this study, we intend to address these deficiencies by analyzing the 
role of 366 human miRNAs as clusters in these four major signaling pathways using an 







The method involves a published lentiviral-based miRNA genetic library that 
contains a large number of human miRNA minigenes [142].  To screen miRNAs that 
specifically target TFs of interest, we utilized luciferase constructs plus the miRNA 
library.  For instance, pTRF-p53-Luc (Systems Biosciences) contains a firefly luciferase 
gene (luc) under the control of a minimal CMV promoter.  This promoter is only 
activated when p53 binds to the p53-specific transcription response elements (TREs), 
eight tandem repeats of ACATGTCCCAACATGTTGTCG.  Similarly, TRE constructs 
for the other TFs are as follows:  pTRF-NF-κB-Luc: four repeats of GGGGACTTTCC; 
and pTRF-AP1-Luc: four repeats of TCCGGTGACTCAGTCAAGCG.  c-Myc activity 
was measured using an E2F2-Luc reporter vector consisting of the E2F2 promotor with 
four distinct E-boxes, CACGTG [143].  The parental vector, pSIF[142], substituted for 
the miRNA construct, serves as a normalization control for miRNA expression.  Rluc 
from pRL-TK (Promega) is used to normalize transfection efficiency and total protein 
synthesis.   
Cell Culture Experiments 
293T and H1299 cells (American Type Culture Collection, Manassas, VA) were 
cultured in DMEM media supplemented with 10% FBS and antibiotics at 37°C with 5% 
CO2.  Lipofectamine LTX (Invitrogen) was used for all transfections according to 
manufacturer’s instructions.  Luciferase assays were conducted using the Dual-Glo® 
Luciferase Assay System (Promega) 48 hours post-transfection in 96-well plates.  
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Relative Luciferse Units (RLU) were normalized to Renilla luciferase expression. The 
parental vector pSIF was used to normalize plate-to-plate variation. Apoptosis was 
measured using an ApoTarget™ Annexin-V FITC Apoptosis Kit (Invitrogen, Carlsbad, 
CA) as described previously [142].  Briefly, transfected cells were washed twice with 
PBS, resuspended in Annexin-V binding buffer, and then incubated in Annexin-V FITC 
and Propidium Iodide Buffer in the dark for 15 minutes at room temperature.  Stained 
cells were then analyzed on an LSR II flow cytometer (BD Biosciences) using FL1 
(FITC) and FL3 (PI) lines. Cell cycle was analyzed as described [144].  Experimental 
groups were analyzed in triplicate, and data represent three independent trials. 
Western Blot 
Total protein was isolated from cells in 6-well plates using M-PER mammalian 
protein extraction reagent (PIERCE, Rockford, IL). Protein concentration was measured 
using a BCA kit (PIERCE, Rockford, IL). 30-50 µg of protein were separated on 12% to 
15% Bis-Tris polyacrylamide gels (Bio-Rad, Hercules, CA) and then transferred to 
PVDF membranes (Bio-Rad). Protein membranes were incubated in blocking buffer (1× 
Tris-buffered saline, pH 7.5, 5% nonfat dried milk, 0.05% Tween 20)  for 2 hours at 
room temperature, followed by anti-p53 antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA), or anti-β-actin antibody (Sigma-Aldrich) overnight at 4 0C. The membranes 
were washed with 1× Tris-buffered saline containing 0.05% Tween 20, incubated with 
horseradish peroxidase-linked goat anti-mouse Ig (Santa Cruz) or goat anti-Rabbit Ig 
(Cell Signaling) for 1 hour at room temperature, washed, and visualized with the 





Boxplots of the luciferase results for all clusters were plotted to show what the 
observations look like for each end point variable (AP-1, NF-κB, c-Myc, or p53).  For 
each end point, residual plots indicated that the observations with log-transformation are 
more likely to be normally distributed and have equal variances among different clusters. 
For each variable, one way analysis of variance (ANOVA) was applied to examine 
whether the observations at log-scale from different clusters are significantly different 
from the overall means at log scale. Residual plots indicated that the log-transformed 
responses are more likely to be normally distributed and have equal variances among 
different clusters.  The Fisher’s least significant difference tests were applied to examine 
which clusters are significantly different from the overall least square mean [145].  Based 
on the analytic results, we painted the boxplots red for the clusters with significantly high 
readings (observations), and green for the clusters with significantly low readings. The 
clusters with a pink diamond are significantly different from the overall mean (Figures 3-
6).     
Results 
miRNA Library Screening 
We used an established TF luciferase-based screen to determine miRNAs 
affecting pathways that regulate TF activity (Figure 2).  293T cells were transfected in 
triplicate with a plasmid containing a firefly luciferase gene under the control of a 
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minimal CMV promoter along with a second plasmid containing a member of our 
miRNA library [142]. Transcription response elements (TRE) corresponding to each TF 
were placed upstream of the promoter.  A third plasmid containing a Renilla luciferase 
gene driven by the HSV-TK promoter served as a normalization control.  Luciferase gene 
expression was measured with a luminometer to determine which miRNA expression 
resulted in inhibition or promotion of TF activity.  Luciferase expression was normalized 
to Renilla luciferase to yield Relative Luminescence Units (RLU) for each miRNA before 
being normalized to the parental vector.  This approach has been used to identify 
individual miRNAs in the p53, NF-κB, and c-MYC pathways [142,144,146].  To analyze 
the impact of miRNA clusters in reporter activities, mean RLU values for each cluster 
were calculated and normalized to the mean values of all miRNAs.  This allowed us to 
determine statistical significance of miRNA regulation of specific TFs when miRNA data 
were stratified into clusters compared to baseline overall miRNA effects.  For each TF, 
clusters with values significantly lower than the overall cluster mean were identified as 
down-regulators of the specified TFs.  Clusters with values significantly higher than the 







 luc TREs 
TF 
TF mRNA 3’ UTR 
Other mRNA 3’ UTR 
or 
microRNA 









Figure 2: Schematic of luciferase-based microRNA screen.   
Figure 2:  Schematic of luciferase-based microRNA screen.  293T cells were co-
transfected with: 1) a vector containing a luciferase gene under control of regulatory 
elements recognized by AP-1, NF-kB, p53, or c-Myc; 2) a member of our microRNA 
library, and 3) a Renilla luciferase vector for normalization of luciferase values.  
Following transfection, cells were analyzed by luciferase assay to measure the effects 
of miRNA regulation of TF-driven luciferase expression. 
TRE: Transcription factor regulatory element, TF: Transcription factor, luc: luciferase, 





Activating protein 1 (AP-1) is a dimeric TF consisting of Jun, Fos, or Activating 
TF (ATF).  Combinations of these subunits allow for hetero- and homo-dimerization, 
resulting in differing DNA recognition and functions of AP-1.  The TRE used in this 
screen is predominantly recognized by the cJun-cFos as well as cJun homodimers to a 
lesser extent [147,148].  AP-1 is activated in response to many signals such as stress, 
bacterial and viral infections, cytokines, growth factors, and oncogenic stimuli.  Post-
translational regulation occurs through interactions with other TFs, proteolytic turnover, 
and phosphorylation [147,149].  Data from the miRNA screen point to five miRNA 
clusters that yield an overall negative effect on AP-1 directed transcription (Figure 3 and 
Table 2).  These clusters may target genes that are upstream of the pathway directly 
regulating AP-1 turnover, or genes within signaling cascades that lead to AP-1 activation.  
Five clusters were found to have an activating effect on AP-1 transcriptional activity.  
One such noteworthy cluster is 10a~196a.  Studies have established a pro-proliferative 
role for this cluster in multiple cancers including pancreatic cancer and acute myeloid 
leukemia [150-152].  This role is consistent with our finding that it positively regulates 
activation of a TF known for its role in promoting proliferation, particularly in the 






  Figure 3. Boxplot showing logarithmic values of AP-1-mediated luciferase 
expression for microRNAs grouped according to cluster. 
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  Figure 3. Boxplot showing logarithmic values of AP-1-mediatedluciferase 
expression for microRNAs grouped according to cluster. Clusters that yielded 
values significantly different from the overall mean are marked with a pink diamond 
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of 
AP-1-driven luciferase gene expression are highlighted in red. MicroRNA clusters 
that down-regulated this expression are marked in green.  293T cells were transfected 





NF-κB is a TF that consists of Rel protein dimers that bind κB sites in the 
promoters of target genes to regulate transcription.  The Rel family of proteins consists of 
five members: p100 and p105 which are proteolytically processed into p50 and p52, 
respectively, and RelA, RelB, and c-Rel, which do not require proteolytic processing.  
The TRE in this screen is specifically recognized by the heterodimer made up of p50 and 
RelA, which is the most abundant form of NF-κB in most cells.  This heterodimer is held 
inactive in the cytoplasm by inhibitors of κB (IκB) [139].  The classical pathway of NF-
κB activation is triggered by exposure to bacterial or viral infections and pro-
inflammatory cytokines such as TNF-α.  These signals go through the Toll-like receptor 
(TLR) to activate IκB kinases (IKK) which phosphorylate IκB, targeting it for ubiquitin-
mediated degradation.  NF-κB is released and translocates to the nucleus to promote 
transcription [139,153].  One of the major functions of NF-κB is inhibition of apoptosis, 
though its role in cancer development and progression is cell-type dependent.  
Suppression of NF-κB activation abrogates transcription of critical anti-apoptotic genes 
such as c-FIIP, cIAP1, cIAP2, and BCL-XL  [153].  This screen revealed seven clusters 
that negatively regulate NF-κB-mediated transcription (Figure 4 and Table 2).  Inhibition 
of NF-κB signaling implies a potential anti-inflammatory role for these clusters.  Five 
clusters were found to up-regulate NF-κB activity.  Among these is cluster 454~301a.  
miR-301a has recently been implicated as an NF-κB inducer in pancreatic cancer [142].  
Cluster 99b~125a was also found to up-regulate NF-κB activity.  A recent study found 
that miR-125a and miR-125b directly target TNFAIP3, a ubiquitin editing enzyme that 
negatively regulates NF-κB activity by disrupting the activation of IKK [120]. 
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  Figure 4. Boxplot showing logarithmic values of NF-κB-mediated luciferase 
expression for microRNAs grouped according to cluster. 
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  Figure 4. Boxplot showing logarithmic values of NF-κB-mediated luciferase 
expression for microRNAs grouped according to cluster. Clusters that yielded 
values significantly different from the overall mean are marked with a pink diamond 
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of 
NF-κB-driven luciferase gene expression are highlighted in red. MicroRNA clusters 
that down-regulated this expression are marked in green.  293T cells were transfected 






c-Myc is a TF that heterodimerizes with Max to bind E-boxes within the 
promoters of its target genes [154].  It is a multifunctional protein that regulates a wide 
variety of cellular processes such as cell cycle progression, growth and metabolism, 
differentiation, and apoptosis [134].  Because of its function in positively regulating 
processes that contribute to tumorigenesis, Myc is a proto-oncogene.  Aberrant 
expression of Myc is seen in the majority of cancers, resulting from genomic 
amplification, or lack of negative regulatory pathways [154].  Our screen returned four 
miRNA clusters that down-regulate Myc-induced transcription (Figure 5 and Table 2).  
Notably, Cluster 512~519a negatively regulates Myc-mediated transcriptional activation.  
Also striking was up-regulation of Myc-mediated transcription by the entire miR-200 
family (Clusters 200c~141 and 200b~429).  In addition, we have confirmed miR-33b as a 










  Figure 5. Boxplot showing logarithmic values of c-Myc-mediated luciferase 
expression for microRNAs grouped according to cluster. 
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  Figure 5. Boxplot showing logarithmic values of c-Myc-mediated luciferase 
expression for microRNAs grouped according to cluster. Clusters that yielded 
values significantly different from the overall mean are marked with a pink diamond 
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of 
c-Myc-driven luciferase gene expression are highlighted in red. MicroRNA clusters 
that down-regulated this expression are marked in green.  293T cells were transfected 






p53 has long been known as the guardian of the genome.  Its transactivational 
functions are well studied and include induction of proapoptotic genes like Puma, Noxa, 
and Bax as well as cell cycle regulatory proteins such as p21 [49].  p53 is maintained at 
low basal levels in the cell by its inhibitory protein, Mdm2 [155].  Mdm2 inhibits p53 
function by acting as an ubiquitin ligase to target p53 for proteasomal degradation as well 
as by binding and blocking the DNA binding domain of p53, inhibiting its activity as a 
TF.  Upon detection of DNA damage, oncogene hyperactivation, or other cellular 
stresses, p53 is phosphorylated on its N-terminus, which blocks inhibition by Mdm2 and 
promotes its binding to p53 response elements.   In our screen, we found 7 miRNA 
clusters that significantly up-regulate p53-mediated luciferase expression (Figure 6 and 
Table 2).  Among these is Cluster512~519a, also known as C19MC.  Comprised of 46 
pre-miRNAs, it is the largest miRNA cluster conserved in primates.  It is an imprinted 
gene, and the paternal allele is expressed specifically in the placenta [130,156].  This 
tissue specificity is noteworthy in the context of its up-regulation of p53 activity.  
Enhanced apoptosis and increased p53 expression in the placenta during pregnancy are 
associated with fetal growth restriction, preeclampsia, intrauterine growth restriction, and 
HELPP syndrome [157,158].  Our screen implicates a role for this miRNA cluster within 
the tightly regulated process of developmental or pathological apoptosis.  Among the 5 
clusters that down-regulated p53-mediated luciferase expression is 200b~429, one of two 
clusters that comprise the miR-200 family (Figure 6 and Table 2).  The miR-200 family is 
largely known as tumor suppressive because of its inhibition of the epithelial-
mesenchymal transition (EMT) through direct targeting of Zeb1 and Zeb2 TFs [116,159].  
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Our data support an oncogenic role for this miR-200 family and we performed ensuing 
studies to examine the role of miR-200a in the p53 pathway (see below).  Cluster 
25~106b also significantly down-regulated p53 activity, and we noted that miR-25 has 














  Figure 6. Boxplot showing logarithmic values of p53-mediated luciferase 




Figure 6. Boxplot showing logarithmic values of p53-mediated luciferase 
expression for microRNAs grouped according to cluster. Clusters that yielded 
values significantly different from the overall mean are marked with a pink diamond 
and annotated in Table 1. MicroRNA clusters that caused significant up-regulation of 
p53-driven luciferase gene expression are highlighted in red. MicroRNA clusters that 
down-regulated this expression are marked in green.  293T cells were transfected with 
















from mean p-value 
AP-1 
Let7g~135a -0.78068 5.14E-03 512~519a 0.183747 1.78E-02 
125b~100 -0.65192 1.92E-02 217~216b 0.567326 4.14E-02 
34bc -0.59466 3.26E-02 10a~196a 0.596606 3.20E-02 
513~514 -0.3289 3.05E-02 454~301a 1.399706 3.86E-04 
339~329 -0.23763 3.22E-03 650 1.636268 3.57E-05 
NF-κB 
215~194 -1.17405 1.90E-04 99b~125a 0.822977 2.81E-03 
30bd -0.87412 9.13E-03 181cd 0.839874 1.22E-02 
125b~100 -0.75574 2.40E-02 192~194 1.167321 1.33E-02 
206~133b -0.74421 2.62E-02 650 1.262463 7.49E-03 
217~216b -0.68132 4.17E-03 454~301a 1.876999 7.89E-05 
513~514 -0.41319 2.39E-02       
c-Myc 
195~497 -0.66248 3.15E-02 17~92a 0.305999 1.74E-02 
193b~365 -0.54136 1.35E-02 23b~24 0.368437 4.00E-02 
512~519a -0.52607 8.16E-17 16~15a 0.432454 4.80E-02 
132~212 -0.52607 1.63E-02 200c~141 0.589838 1.08E-03 
      200b~429 0.312486 5.25E-03 
p53 
200b~429      -0.83273 6.44E-04 532~500     0.295012 2.61E-02 
30ec               -0.69189 4.46E-03 512~519a   0.444204 1.78E-10 
425~191         -0.61609 1.12E-02 99a~125b   0.522585 3.12E-02 
653~489         -0.56796 1.93E-02 296~298     0.712016 3.71E-02 
25~106b         -0.53544 7.25E-03 371~373     0.747797 2.14E-03 
      454~301a   0.766234 2.49E-02 
      650 0.877633 1.03E-02 
 
  




The miR-200 family is comprised of two clusters (Figure 1).  Cluster 200b~429 is 
located on chromosome 1 and contains miR-200a, miR-200b, and miR-429.  Cluster 
200c~141 is located on chromosome 12 and contains miR-200c and miR-141.  The most 
thoroughly studied function of the miR-200 family is inhibition of EMT.  EMT is 
characterized by cellular acquisition of mesenchymal morphology and phenotypes and is 
largely associated with tumor metastasis.  In particular, the TFs Zeb1 and Zeb2 are 
responsible for repressing transcription of E-cadherin and other epithelial markers to 
promote EMT [115,160].  The miR-200 family directly targets the 3' UTRs of Zeb1 and 
Zeb2 to inhibit their expression, and Zeb1 and Zeb2, on the other hand, bind the 
promoters of both miR-200 family clusters to reciprocally inhibit their transcription 
[124].  This miRNA family inhibits proliferation as well as EMT through its targeting of 
Zeb1 and Zeb2 [161].  Recently, however, new tumor-suppressor targets of the miR-200 
family have been discovered, suggesting this miRNA family may have a pro-proliferative 
function [5,102,162].  In addition, a recent study has investigated the miR-200 family’s 
promotion of an epithelial morphology in the context of a mesenchymal-epithelial 
transition, thus promoting metastatic colonization, and providing further evidence for an 
oncogenic role for this miRNA family [123].   
Our screen revealed a p53-suppressing role for cluster 200b~429, which contains 
miR-200a, miR-200b, and miR-429.  TargetScan predicts a miR-200a binding site in the 
3’ UTR of p53 (Figure 7A). This predicted target is conserved between humans and 
chimpanzees.  To determine direct targeting of p53 by miR-200a, a luciferase assay was 
performed using constructs with a wild type 3’ p53 UTR (WT) or a 3’ UTR with a 
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mutated miR-200a binding site (Mut) downstream of a luciferase reporter gene.  
Luciferase assay was performed to measure differential reporter expression resulting 
from this binding site mutation in p53-null H1299 cells (Figure 7B).  Compared to empty 
vector control, miR-200a caused a significant reduction in WT construct luciferase 
expression.  This reduction of expression was not seen in cells with the mutant 3’ UTR.   
This suggests that miR-200a directly targets the 3’ UTR of the human p53 gene.  Western 
blot was performed to determine the effects of miR-200a on p53 protein levels.  H1299 
cells were transfected with miR-200a or its empty vector control, and either p53 coding 
sequence with a wild type 3’ UTR (WT) or that with a mutated miR-200a binding site in 
its 3’ UTR (Mut). Compared to the control, miR-200a caused a significant down-
regulation of p53 protein levels in cells with a WT 3’ UTR, but not those with a Mut 3’ 
UTR (Figure 8A).  These results show that direct targeting of the p53 3’ UTR by miR-
200a down-regulates p53 at the protein level.  To determine the functional significance of 
p53 suppression by miR-200a, we analyzed apoptosis and cell cycle in response to miR-
200a over-expression in H1299 cells containing a p53 expression cassette with either WT 
or Mut 3’ UTR. We found that re-expression of p53 in H1299 cells led to significant cell 
apoptosis and cell cycle arrest at the G1 phase (G1 arrest) even in the absence of DNA 
damage (Figure 8B and 8C), in agreement with previous reports [163-165].    miR-200a 
significantly decreased apoptosis in H1299 cells with the WT p53 construct (Figure 8B).  
Apoptosis was unaffected in cells containing the Mut p53 construct.  In addition, G1 
arrest was also inhibited by miR-200a compared to the vector control (50.7% versus 60.1, 
P≤0.05) only when the exogenous p53 had a WT 3’ UTR (Figure 8C). Taken together, 
these results provide a new mechanism of oncogenic action for miR-200a.  By directly 
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targeting the 3’ UTR of p53, miR-200a down-regulates p53 protein expression, resulting 



















Figure 7.  miR-200a directly targets the human p53 gene.  (A) Schematic 
representation of miR-200a: p53 3'UTR. Top: seed sequence base paring between 
miR-200a and the 3'UTR of p53 mRNA. Bottom: p53 constructs with the wild type 
miR-200a binding site (WT) or a mutated miR-200 binding site (Mut) in the 3'UTR. 
(B) A reporter assay to determine whether the p53 3'UTR is targeted by miR-200a. Y 
axis denotes relative luminescent units (luc/Rluc) in H1299 cells expressing WT or 
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Figure 8.  miR-200a downregulates p53 protein expression and inhibits apoptosis.  
(A) Western blotting analyses of H1299 cell extracts. H1299 cells were transfected 
with miR-200a and WT or Mut p53 3’UTR constructs. (B) Apoptosis assay of H1299 
cells transfected as in C. E. Cell cycle analysis of H1299 cells transfected as in (C) The 
Y axis denotes events (the number of cells) and the X axis denotes the emitted 
fluorescent light of the DNA dye (PI), that is, DNA content. Values like indicate the 











Most miRNA studies revolve around finding novel targets of single miRNAs, yet 
half of all miRNAs are co-expressed as clusters [88].  Most of the miRNAs within 
clusters are likely to be transcribed as a whole unit, so these coexpressed miRNAs shall 
be investigated together for their biological and pathological function.  By stratifying our 
screen of miRNAs that target TF signaling pathways into miRNA clusters, we were able 
to collect data that describes the effects of an entire miRNA cluster on a signaling 
pathway culminating in regulation of a major TF.  Several mechanisms exist behind 
multiple coexpressed miRNAs regulating a wide variety of targets, thus the modus 
operandi of miRNA clusters is not fully understood.   Individual miRNAs are predicted 
to, and have been found to target a wide array of genes and affect multiple cellular 
functions [41,166].  Based solely on this, a miRNA cluster could potentially target any 
and all cell signaling pathways.  However, bioinformatics, as well as an increasing 
number of molecular biology approaches have parsed out a much more ordered pattern of 
target suppression by miRNA clusters [89-91,133].  miRNA clusters are predicted to 
target interacting members of protein complexes [89], multiple proteins within a single 
pathway or biological process [90,133], or multiple clustered miRNAs may 
simultaneously target and strongly repress a single key regulator of a pathway [167].  In 
this way, rather than the small scale fine tuning of hundreds of targets [87], a cluster 
would provide a large combinatorial impact on an entire biological process or pathway.  
In miRNA clusters comprised of closely related family members, for example both 
clusters of the miR-200 family or many members of C19MC, similar or same seed 
sequences provide a clear mechanism for multiple cluster members to target identical sets 
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of genes [123].  This combinatorial system of multiple clustered miRNAs regulating an 
entire system does not preclude the presence of a single major effector miRNA within a 
cluster regulating a specific pathway [90].  Xu and Wong propose this mechanism for 
cluster mmu-miR-183-96-182, which is predicted to control 12 signaling pathways.  miR-
96 is predicted to target the majority of the genes within these pathways, indicating it as 
the major effector miRNA of this cluster [90].  Cluster 17~92a, is a well-studied 
oncogenic cluster whose most oncogenic member, miR-19, has been experimentally 
validated as the most active player in the oncogenic process [168].  The 25~106b cluster, 
an ortholog of 17~92, significantly down-regulated p53 reporter activity.  We have 
verified that miR-25 directly targets the p53 gene [144].  It is noted that each miRNA in 
the 25~106b cluster is upregulated in multiple myeloma, a cancer with little p53 mutation 
[169]. miR-25 is the most significantly upregulated miRNA in multiple myeloma, and its 
expression is inversely correlated with p53 mRNA levels, suggesting that miR-21 
upregulation could be responsible for p53 inactivation in cancers without p53 mutation 
[144].  How other members of the 25~106b cluster upregulate p53 transactivational 
activities, however, remains elusive. Similarly, we have verified that miR-301a up-
regulates NF-κB by inhibiting Nkrf [142], yet the role of miR-454 (the other member of 
the 301a~454 cluster) in the NF-κB pathway needs further investigation.   
We experimentally pursued the down-regulation of p53 activity by cluster 
200b~429 and demonstrated the direct targeting of p53 by miR-200a. miR-200a and its 
orthologs, miR-200b, miR-200c, and miR-141 were first found tumor suppressors as they 
inhibit EMT through targeting Zeb1 and Zeb2 [115,116].  Recently, studies have begun 
investigating the role of miR-200a in the reverse process, mesenchymal-epithelial 
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transition, which enhances the metastatic potential of cancer cells [123].  Down-
regulation of p53 and subsequently apoptosis and G1 arrest by miR-200a illuminates a 
novel function for this miRNA.  This, coupled with emerging studies that show evidence 
for an oncogenic function for miR-200a and its family members [5,102,162], provides a 
strong foundation for the oncogenic potential of miR-200a.   
While our screen provides new, preliminary experimental data regarding the 
effects of miRNA clusters on TF pathways, there are several limitations that must be 
considered.  First, this screen was performed with a single cell line (293T), which does 
not account for any bias that may arise from tissue or cell-type specific targeting.  
Second, our screen may return false negatives or positives because other cellular changes 
may compromise the luciferase reading.  For example, miR-34c is a tumor suppressor, 
identified as such by its direct targeting and repression of c-Myc [168].  However, cluster 
34bc was not found in this screen to down-regulate c-Myc activity.  Finally, single 
transient transfections of miRNA-containing plasmids do not replicate endogenous 
miRNA levels, which may be subject to further regulation when the entire cluster is 
expressed.  This may bias the screen toward miRNAs that are expressed at low 
endogenous levels. These limitations can be mitigated by further experimental validation 
using multiple cell lines or performing miRNA inhibition experiments [144,146]. 
To summarize, this study provides a panoramic view of miRNA clusters’ effects 
on AP-1, NF-B, c-Myc, and p53 signaling pathways and will serve as a base for 





THE ROLE OF MIR-200A IN MAMMALIAN EPITHELIAL CELL 
TRANSFORMATION 
Chapter Overview 
Cancer is a multistep disease that begins with malignant cell transformation and 
frequently culminates in metastasis and death.  MicroRNAs (miRNAs) are small 
regulatory 21-25-nt RNA molecules and are frequently dysregulated in cancer.  miR-200a 
is a member of the miR-200 family, which are known to be strong inhibitors of the 
epithelial to mesenchymal transition.  As such, the tumor suppressive role of miR-200a in 
oncogenesis has been well studied; however, recent studies have found a proliferative 
role for this miRNA as well as a pro-metastatic role in the later steps of cancer 
progression.  Little is known about the role of this miRNA in the early stages of cancer, 
namely, malignant cell transformation.  Here we show that miR-200a cooperates with 
Ras to enhance malignant transformation of immortalized mammary epithelial cells.  
Furthermore, miR-200a induces cell transformation and tumorigenesis in 
immunocompromised mice by cooperating with a Ras mutant that activates only the 
RalGEF effector pathway, but not Ras mutants activating PI3K or Raf effector pathways.  
This transformative ability is in accordance with miR-200a targeting Fog2 and p53 to 




demonstrate a role for miR-200a in malignant cell transformation and provide a specific 
cellular context where miR-200a acts as an oncomiR rather than a tumor suppressor by 
cooperating with an oncogene in the classical two-hit model of malignant cell 
transformation. 
Introduction 
Cancer is an often fatal disease that requires multiple steps to progress from a 
normal state to full phenotypic disease [1,170].  Cancer mortality, while comprising one 
quarter of all deaths in the United States, is declining, due largely to improvements in 
screening and detection.  Diagnosis of early stage cancer is strongly associated with 
better survival [1-3,171].  Thus it is crucial to understand the molecular events that occur 
early in this progressive disease.     
Malignant cell transformation is the initiating step of cancer progression [172].  
During this process, a cell must bypass senescence and avoid apoptosis, allowing for 
uncontrolled proliferation, which leads to formation of a primary tumor [12].  The hyper-
proliferative, anti-apoptotic phenotypes that arise during malignant cell transformation 
are conferred by genetic mutations and abnormalities that upregulate proto-oncogene 
activity and ablate tumor suppressor gene function [173].  The first oncogene/tumor 
suppressor combinations associated with cell transformation were investigated by in an 
attempt to delineate endogenous, non-viral proto-oncogenes [79,81].  The classical model 
of cell transformation identified the cooperation between the Ras and Myc oncogenes in 
selecting for a dominant-negative p53 tumor suppressor mutation and transforming 
primary rodent cells [81].  Numerous transforming oncogenes and tumor suppressor 
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mutations have been identified since these landmark studies [82], demonstrating the 
complexity of cancer initiation. 
Recently, noncoding RNAs, e.g. microRNAs (miRNAs), have garnered interest as 
potent mediators of malignant cell transformation and cancer progression [100,106,129]. 
miRNAs  are a regulatory class of small RNAs that bind the 3’ UTR of target mRNA to 
post-transcriptionally repress gene expression [84]. miRNAs are frequently dysregulated 
in cancer through altered epigenetic modifications, deletions, translocations, and 
amplifications [100,103]. The subsequent changes in expression patterns and/or function 
result in differential repression of target genes. By repressing expression of oncogenes or 
tumor suppressors, a miRNA may function as a tumor suppressor or oncogene, 
respectively [129]. 
Among miRNAs dysregulated in cancer, miR-200a has emerged as a key 
mediator of the oncogenic process, though its overall role during cancer progression is 
not clear.  Gene expression profiling reports that miR-200a is frequently down-regulated 
in cancer, including melanoma, breast, and nasopharyngeal cancers [118,119,121]. Its 
most well studied function is the suppression of Zeb1/2 transcription factors to inhibit the 
epithelial to mesenchymal transition (EMT) and promote a more stable, epithelial 
phenotype [115,124].  EMT is a crucial early step in the progression of transformed 
primary tumor cells into invasive metastatic cells that invade local stroma, travel through 
vasculature, and colonize distant sites in the body [4,174].  These metastases are 
responsible for the gross majority of cancer related deaths [171].  By blocking EMT and 
inhibiting metastasis, miR-200a functions as a tumor suppressor [116,124].   
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However, miR-200a has also been found to promote oncogenesis.  miR-200a is 
overexpressed in several cancers including endometrial, pancreatic, and ovarian cancers 
[105,175,176].  Our studies demonstrate a specific role for miR-200a in early cancer 
progression that may apply to such clinical cases. Recent studies show that mesenchymal 
to epithelial transition (MET), the reversal of EMT, is a later step in metastasis that 
allows motile, invasive cells to revert back to a stable epithelial phenotype more 
conducive to forming new metastatic tumors at distant sites [177].  By inducing an 
epithelial phenotype in this context, miR-200a promotes metastasis [5,123,178]. In 
addition to its involvement in EMT/MET, a limited number of studies have observed a 
hyper-proliferative role for miR-200a including stimulation of PI3K signaling in 
hepatocellular carcinoma cells and up-regulation of miR-200a in a rat model of 
hepatocellular carcinoma [102,179].  My recent study demonstrates the anti-apoptotic 
function of miR-200a due to its direct targeting of p53 [53] (Chapter 2).  In this study, we 
determined the effect of miR-200a overexpression on transformation of rodent cells and 
immortalized human MCF10a cells and characterized the underlying mechanism of the 
ability of miR-200a to cooperate with Ras to transform MCF10a cells.  
Experimental Procedures 
Cell Culture 
Rat kidney epithelial RK3E cells and human embryonic kidney 293T cells 
(American Type Culture Collection, Manassas, VA) were cultured in DMEM media 
supplemented with 10% FBS and antibiotics at 37°C with 5% CO2. Human mammary 
epithelial MCF10A cells were cultured in DMEM/F12 supplemented with 5% horse 
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serum, 20 ng/mL EGF (Invitrogen), 0.5 mg/mL Hydrocortisone (Sigma), 100 ng/mL 
Cholera Toxin (Sigma), 10 ug/mL Insulin (Humulin), and antibiotics at 37°C with 5% 
CO2.  
miRNA Screen 
RK3E cells were transfected using Lipofectamine LTX/Plus reagent according to 
manufacturer instructions with individual miRNAs from our laboratory’s miRNA library 
comprised of 366 human miRNA minigenes in the lentiviral PSIF vector [180].  After 48 
hrs, wells were visually inspected for three dimensional foci formation. 
Transfection and Viral Transduction 
Lipofectamine LTX-plus (Invitrogen) was used for all transfections according to 
manufacturer's instructions.  For lentivirus production, 293T cells were transiently co-
transfected, 24hrs post plating in 6-well plates, with 2µg of pSIF vector, or miRNA, 
1.4µg of pVGV-S and 0.7µg of pFIV-34N packing and expression vectors, respectively.  
Lentivirus-containing supernatant was collected after 48 hours, centrifuged to remove 
cellular debris, and supplemented with 8 µg/mL Polybrene (American Bioanalytical) 
before transducing target MCF10A or RK3E cells.  For retrovirus production, 3 µg of the 
retroviral vectors containing constitutively active RasG12V mutant (Addgene plasmid 
1768), c-Myc (Myc construct from Addgene plasmid 16011 cloned into plasmid 12269), 
p53dd (Addgene plasmid 9058), or RasG12V effector pathway mutants (Addgene 
plasmids 12274, 12275, 12276) [18] were transfected into Phoenix-Ampho cells, and 
virus collection and transduction were performed as for Lentivirus.  G418 (200 µg/mL), 
Puromycin (1 µg/mL), or Hygromycin (8 µg/mL) were used to select for positively 
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transduced cells.  Cells were transduced three timesmiR-200a expression levels, as 
measured by Taq-Man QRT-PCR expression assay (Invitrogen), ranged from a 5 to 15 
fold increase above vector control (Data not shown).     
Acini Formation in Matrigel 
Matrigel (Corning) was used to coat the well bottoms of a 12-well chamber slide 
(Ibidi).  5,000 positively drug-selected exponentially growing MCF10A cells suspended 
in 2% Matrigel were layered over top of the first Matrigel layer and allowed to grow 5 or 
14 days.  Acini were fixed with ethanol while still in Matrigel to prevent disruption of 
morphology, blocked with goat serum and incubated first with anti-E Cadherin or 
Cleaved caspase-3 antibodies (Cell Signaling) overnight at 4° and then Alexa488-coupled 
goat anti-rabbit secondary antibodies for 2 hrs room temperature.  Slides were visualized 
by confocal microscopy. 
Colony formation assay 
Six well plates were coated with a bottom layer of 0.5% noble agar (Sigma-
Aldrich) and 2000 RK3E or MCF10A cells were suspended in a top layer of 0.2% noble 
agar in triplicate. The cells were maintained at 37˚C in a humidified 5% CO2 atmosphere 
for two weeks. Fresh media was added at regular intervals to prevent the plates from 
drying out.  Resulting colonies were stained with 0.05% Crystal Violet and destained 
with water.  Colonies were counted and imaged using a dissection microscope coupled to 
a digital microscope imager (Celestron).  The experiment was performed three times, 
once for each level. 
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Cell Cycle Analysis 
For synchronization, MCF10A cells were progressively deprived of serum and 
growth factors over 24 hours, then stimulated with complete media for 18 hours.  Cells 
were collected by trypsinization and washed twice in 1X PBS. Cells were fixed in 1ml of 
ice-cold 70% ethanol at 4˚C overnight. Cells were then washed twice with 1X PBS and 
stained with a solution of 50 µg/ml Propidium Iodide, 100 µg/ml Ribonuclease A, and 
0.2% Triton X-100 diluted in PBS for 30 mins at 4˚C.  Flow cytometry was performed 
with a FACScan Flow Cytometer.  A minimum of 10,000 cells per sample were collected 
and the FACS files were analyzed using FlowJo software (Tree Star Inc.) for cell cycle 
analysis [28]. 
Cell Migration 
Transwell (Boyden) chambers (Invitrogen, Carlsbad, CA), with a pore size of 
8µm, were placed in triplicate into 12-well plates.  Complete MCF10A media, which 
served as a chemoattractant, was added to wells beneath the Transwell chamber.  D283 
cells (1×104) in low serum media were added to the Transwell chamber and the plates 
were then incubated at 37˚C in a humidified 5% CO2 atmosphere for 24 hrs. The cells 
were fixed with methanol for 10 mins and stained with 0.4% crystal violet for 2 hrs. Non-
migrated cells on the upper side of the filter were removed with a cotton swab, and the 
filter was mounted on microscope glass slides.  Slides were imaged using a dissection 





Total protein was isolated from cells in 6-well plates using RIPA (Cell Signaling). 
Protein concentration was measured using a BCA kit (Pierce). 30–50 µg of protein were 
separated on 12% to 15% Bis-Tris polyacrylamide gels (Bio-Rad) and then transferred to 
PVDF membranes (Bio-Rad). Protein membranes were incubated in blocking buffer (1× 
Tris-buffered saline, pH 7.5, 5% nonfat dried milk, 0.05% Tween 20) for 2 hours at room 
temperature, followed by phospho-p53, p53, PTEN, phospho-Akt, Akt, phospho-Erk, or 
Erk antibody (Cell Signaling), Fog2 antibody (Santa Cruz Biotechnology) or β-actin 
antibody (Sigma-Aldrich) overnight at 4°C. The membranes were washed with 1× Tris-
buffered saline containing 0.05% Tween 20, incubated with horseradish peroxidase-
linked goat anti-mouse Ig (Santa Cruz) or goat anti-Rabbit Ig (Cell Signaling) for 1 hour 
at room temperature, washed, and visualized with the SuperSignal West Dura 
Chemiluminescent Substrate kit (PIERCE). 
Mice 
Athymic male nude (Foxn1nu/Foxn1nu) mice (5 weeks old) were purchased from 
The Jackson Laboratory (Bar Harbor, ME) and maintained in the University of 
Louisville’s AAALAC-accredited animal facility. All animal studies were conducted in 
accordance with National Institutes of Health animal use guidelines, and a protocol 
approved by the University of Louisville’s Institutional Animal Care and Use Committee. 
Exponentially growing cells were harvested and injected subcutaneously (5.0x105 
cells/animal) into nude mice (six per group).  Each mouse was injected in each flank with 
MCF10A cells stably over-expressing a Ras effector mutant alone in one flank, and 
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MCF10A cells stably over-expressing the same Ras effector mutant in combination with 
miR-200a in the other flank.  Side of injection was randomized.  Tumor size was 
monitored once per week for 10 weeks before sacrificing.  Tumors were harvested and 
immediately formalin fixed.  Tumors were embedded in paraffin, and tissue sections were 
stained with hematoxylin and eosin. 
Statistical Analysis 
Colony formation data was analyzed by multivariate analysis of variance 
(MANOVA) with T tests post hoc to look for individual effects with standard errors 
corrected for multiple comparisons.  Cell proliferation data were analyzed by linear 
regression modeling with T tests post hoc to determine individual effects using standard 
errors corrected for multiple comparisons.  Cell Cycle Distribution was analyzed by 
generalized linear models comparing G1 to combined S/G2 phases with binomial 
response variables and parameters estimated by maximum likelihood.  Log odds ratios 
were further analyzed by T tests post hoc to evaluate individual effects using standard 























Group 1 Group 2 colonies t value p value 
 vector miR-200a 3.33E-01 4.05E-02 4.84E-01 
 vector Ras 6.40E+01 7.77E+00 2.69E-07 *** 
vector cMyc 1.37E+01 1.66E+00 5.76E-02 
 vector p53dd 2.30E+01 2.79E+00 6.24E-03 ** 
vector Ras + cMyc 1.10E+01 1.89E+00 3.80E-02 * 
vector miR-200a + Ras 1.45E+02 1.24E+01 2.93E-10 *** 




p53dd -5.67E+00 -4.87E-01 6.84E-01 
 miR-200a miR-200a + Ras 2.09E+02 1.79E+01 8.86E-13 *** 
Ras miR-200a + Ras 1.45E+02 1.25E+01 2.82E-10 *** 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05  
   
Table 3.  Statistical Analyses of colony formation in soft agar:  miR-200a, oncogenes. 
MCF10A cells stably overexpressing miR-200a alone or in combination with the 
indicated oncogenes. 
 
MCF10A COLONY FORMATION ASSAY - miR-200a + Oncogenes 
 
Coefficients: (1 not defined because of singularities) 
                  Estimat Error t value Pr(>|t|) 
(Intercept)      -1.023e-14  5.821e+00   0.000    1.000     
miR200a           3.333e-01  8.233e+00   0.040    0.968     
ras               6.400e+01  8.233e+00   7.774 3.68e-07 *** 
cmyc              1.367e+01  8.233e+00   1.660    0.114     
p53dd             2.300e+01  8.233e+00   2.794    0.012 *   
ras:cmyc         -6.667e+01  1.164e+01  -5.726 1.98e-05 *** 
miR200a:ras       1.447e+02  1.164e+01  12.425 2.87e-10 *** 
miR200a:cmyc     -1.300e+01  1.164e+01  -1.117    0.279     





















Group 1 Group 2 colonies t value p 
value 
 
vector miR-200a 2.33E+00 2.18E-01 0.415  
vector E37G 5.67E+00 5.31E-01 0.301  
vector T35S 2.33E+00 2.18E-01 0.415  
vector Ras 1.16E+02 1.09E+01 0.000 *** 
vector Y40C 1.80E+01 1.69E+00 0.055  
vector miR-200a + E37G 4.33E+01 2.87E+00 0.005 ** 
vector miR-200a + T35S 9.33E+00 6.18E-01 0.272  
vector miR-200a + Y40C 2.33E+00 1.55E-01 0.440  
miR-200a + 
E37G 
miR-200a 4.90E+01 3.24E+00 0.002 ** 
miR-200a + 
E37G 
E37G 4.57E+01 3.02E+00 0.004 ** 
miR-200a + 
T35S 
miR-200a 1.17E+01 7.73E-01 0.225  
miR-200a + 
T35S 
T35S 1.17E+01 7.73E-01 0.225  
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05    
 
Colony formation - miR-200a + Ras Effector Mutants 
 
Coefficients: (1 not defined because of singularities) 
                  Estimate Std. Error t value Pr(>|t|)     
(Intercept)     -1.641e-14  7.551e+00   0.000   1.0000     
miR200a          2.333e+00  1.068e+01   0.218   0.8295     
rase37g          5.667e+00  1.068e+01   0.531   0.6022     
rast35s          2.333e+00  1.068e+01   0.218   0.8295     
raswt            1.160e+02  1.068e+01  10.862 2.47e-09 *** 
rasy40c          1.800e+01  1.068e+01   1.685   0.1092     
miR200a:rase37g  4.333e+01  1.510e+01   2.869   0.0102 *   
miR200a:rast35s  9.333e+00  1.510e+01   0.618   0.5443     
miR200a:raswt           NA         NA      NA       NA     
miR200a:rasy40c  2.333e+00  1.510e+01   0.154   0.8789 
Table 4  Statistical Analyses of colony formation in soft agar: miR-200a, Ras mutants.  
MCF10A cells stably overexpressing miR-200a alone or in combination with the 






Group 1 Group 2 Slope t value p value  
vector miR-200a 0.105455 3.052862 0.001939 *** 
vector Ras 0.13628 16.74201 0 *** 
vector miR-200a + Ras 0.014801 1.285814 0.102695 *** 
miR-200a + 
Ras 
miR-200a 0.009257 0.267985 0.394996  
miR-200a + 
Ras 
Ras -0.02157 -1.87369 0.96611  














Cell Proliferation Curve 
 
Coefficients: 
                  Estimate Std. Error t value Pr(>|t|)     
(Intercept)       0.116063   0.020842   5.569 1.54e-06 *** 
time              0.070912   0.006865  10.330 3.19e-13 *** 
time:miR200a      0.034543   0.008140   4.244 0.000115 *** 
time:ras          0.065368   0.008140   8.031 4.29e-10 *** 
time:miR200a:ras -0.056111   0.011511  -4.874 1.53e-05 *** 
--- 
Signif. codes:  0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
Residual standard error: 0.08805 on 43 degrees of freedom 
Multiple R-squared:  0.9309,    Adjusted R-squared:  0.9245  
F-statistic: 144.9 on 4 and 43 DF,  p-value: < 2.2e-16 
 
Table 5.  Statistical Analysis of Cell Proliferation Data.  MCF10A cells stably 














Group 1 Group 2 log odds 
estimate 
Fold Change z value p value 
vector miR-200a -0.22044 0.802165767 -9.1659 0.00003 
vector Ras -0.04985 0.95137212 -2.23643 0.01266 
vector cMyc -0.51718 0.596199462 -24.0214 0.00003 
vector p53dd -0.46435 0.628543526 -19.726 0.00003 
vector Ras + cMyc 2.7934 16.33646948 93.29993 0.99997 
vector miR-200a + 
Ras 
2.2798 9.774725269 70.16928 0.99997 
vector miR-200a + 
cMyc 
2.12701 8.389743937 67.73917 0.99997 
vector miR-200a + 
p53dd 
1.77622 5.907483872 53.82485 0.99997 
miR-200a 
+ Ras 
miR-200a 0.26847 1.307961738 8.263158 0.99997 
miR-200a 
+ Ras 






Table 6.  Statistical Analyses of Cell Cycle Data.  MCF10A cells stably 
overexpressing miR-200a alone or in combination with the indicated oncogenes. 
CELL CYCLE DATA 
 
Coefficients: (1 not defined because of singularities) 
                 Estimate Std. Error z value Pr(>|z|)     
(Intercept)       0.98074    0.01762   55.66   <2e-16 *** 
miR200a          -1.20118    0.02405  -49.94   <2e-16 *** 
ras              -1.03059    0.02229  -46.23   <2e-16 *** 
cmyc             -1.49792    0.02153  -69.56   <2e-16 *** 
p53dd            -1.44509    0.02354  -61.40   <2e-16 *** 
ras:cmyc          1.81266    0.02994   60.53   <2e-16 *** 
miR200a:ras       1.29906    0.03249   39.99   <2e-16 *** 
miR200a:cmyc      1.14627    0.03140   36.51   <2e-16 *** 




miR-200a transforms immortalized rat epithelial cells 
The RK3E cell line is an E1A-immortalized rat kidney epithelial cell line, whose 
defining characteristic is monolayer growth under normal conditions, and foci formation 
under transforming conditions such as Ras activation or Myc overexpression [181-183]. 
In order to determine the role of miRNAs in cell transformation, RK3E cells were 
transiently transfected with individual miRNAs from our library of 366 miRNA genes 
[180] and visually screened for foci formation (Figure 9A).  A construct expressing c-
Myc was used as a positive control [154]. Negative vector control-expressing cells 
formed no foci.  Of the 366 miRNAs screened miR-141 and let-7e formed about the same 
number of foci as c-MYC, and miR-200a formed more foci than c-Myc.  These three 
miRNAs were selected for an ensuing stringent cell transformation experiments.  We 
stably infected RK3E cells with lentivirus made from each of these three miRNAs or 
vector control and assayed them for anchorage-independent growth in soft agar.  All three 
miRNAs induced colony formation in soft agar (Figure 9B).   
In order to determine tumorigenicity of these miRNAs, RK3E cells stably 
expressing each of these miRNAs were subcutaneously injected into nu/nu mice.  Cells 
expressing miR-141 or miR-200a formed orthotopic subcutaneous tumors (Figure 10), 
but let-7e-expressing cells did not produce tumors (data not shown).  miR-200a and miR-
141 are family members with identical seed sequences, thus miR-200a alone was 
analyzed further.   
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To determine potential mechanisms underlying this cell transformation, we 
analyzed the expression of miR-200a target genes [102,184-186].  Consistent with the 
literature, Western blot analyses showed that in RK3E cells expressing miR-200a, the 
epithelial marker, E-cadherin, was up-regulated, and the mesenchymal marker, Vimentin, 
was down-regulated compared to vector control (Figure 11A).  Furthermore, expression 
of the negative regulators of the PI3K/Akt pathway, Fog2 and Pten, was down-regulated, 
concomitant with an increase in Akt phosphorylation (Figure 11B). 
We next determined whether miR-200a acts as a driving force in cell 
transformation. We employed the classical two-hit model of primary rodent cell 
transformation by combining miR-200a with Ras, c-Myc, or p53dd in mouse embryonic 
fibroblasts (MEFs).  miR-200a overexpression in MEFs induces an initial increase in 
proliferation; however, miR-200a expression alone, or in combination with either Ras or 
c-MYC was unable to transform MEFs (data not shown).  p53dd is known to immortalize 
MEFs, however miR-200a was unable to cooperate with this tumor suppressor mutation 
to transform these cells. Ras and Myc coexpression was able to transform primary MEFs.  
Taken together, these results suggest that other genetic pathways active in RK3E cells, 
but not in primary MEFs, are involved in miR-200a-mediated cell transformation and that 









Figure 9.  miR-200a transforms RK3E cells. 
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Figure 9.  miR-200a transforms RK3E cells.  (A)  Schematic of foci formation induced by transient 
transfection of individual miRNA from our library of 366 miRNA minigenes.  (B)  Phase contrast 
microscopy of 3-dimensional colonies formed in soft agar by RK3E cells stably overexpressing the 













Figure 10. miR-200a induces tumorigenesis of RK3E cells in 
immunocompromised mice 
  miR-141                     miR-200a                   vector 
Figure 10.  miR-200a induces tumorigenesis of RK3E cells in 
immunocompromised mice.  Subcutaneous tumor formation of RK3E cells 
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Figure 11.  miR-200a regulates EMT and stimulates Akt activity. 
Figure 11.  miR-200a regulates EMT and stimulates Akt activity.   
(A)  Western blot for the mesenchymal marker Vimentin and the epithelial marker, E. Cadherin in 
RK3E cells lenti-virally infected with miR-200a or empty vector control.  (B)  Western blot for 




miR-200a augments Ras transformation of immortalized human mammary 
epithelial cells. 
In order to determine the role of the proliferative effects of miR-200a in human 
cells, we chose the immortalized yet untransformed mammary epithelial cell line, 
MCF10A, from a patient with fibrocystic disease [187].  This cell line is readily 
transformed by overexpression of Ras or Myc, and normal morphology in three-
dimensional cell culture is disrupted by loss of p53 signaling [188-190].  Consistent with 
our efforts to determine oncogenic cooperativity, we stably infected this cell line with 
miR-200a alone, or in combination with Ras, c-MYC, or p53dd.  The Ras construct 
harbors a G12V mutation, rendering it constitutively active.  p53dd is a truncated form of 
the carboxy terminus of the p53 protein that binds wild type p53, resulting in a dominant 
negative repression of p53 function [191].  To test for transformation, cells were assayed 
for anchorage-independent growth in soft agar (Figure 12, 13).  miR-200a alone did not 
transform MCF10A cells.  When miR-200a was expressed in combination with c-Myc or 
p53dd, colony formation was not significantly increased compared with that of either 
oncogene alone.  However, colony formation increased more than three times in cells 
expressing miR-200a in combination with Ras than that in cells expressing Ras alone 
(Figure 13).  Coexpression of Ras and c-Myc induced colony formation, but surprisingly, 
their combined effects were not synergistic, that is, their combined effect did not show an 
increase greater than the addition of both oncogene’s individual effects.  MF10A cells 
expressing miR-200a at 5-fold, 10-fold, and 15-fold increases above vector control were 
transduced with empty vector or Ras, and assayed for colony formation.  There was no 
difference in the number of colonies formed in response to varying levels of miR-200a 
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expression (Data not shown).  Cells with a 10-fold increase in miR-200a expression were 
used for subsequent experiments. 
miR-200a synergizes with Ras to inhibit apoptosis. 
We next analyzed these cells for changes in cell cycle progression (Figure 14, 15).  
Compared to vector control, all experimental groups caused a decrease in G1 arrest.  
Consistent with its effects on colony formation, Ras and Myc coexpression had the 
smallest effect, decreasing G1 arrest from 70.93% to 55.52%.  Compared to p53dd  
alone, miR-200a in combination with p53dd  caused the greatest increase in cell cycle 
progression, decreasing G1 arrest from 38.48% to 28.88%.  Surprisingly, G1 arrest was 
unchanged between cells expressing Ras alone, and miR-200a in combination with Ras.  
Furthermore, compared to miR-200a alone, G1 arrest in cells expressing miR-200a 
combination with Ras increased from 43.83% to 50.15%.  Compared to cMyc alone, 
miR-200a with cMyc did not change G1 arrest levels. This indicates that induction of cell 
cycle progression is not responsible for the combinatorial effect between Ras and miR-
200a on cell transformation. We next generated a cell proliferation curve in order to 
compare growth rates of cells expressing miR-200a alone and cells expressing miR-200a 
in combination with Ras (Figure 16).  miR-200a alone and in combination with Ras 
significantly increased proliferation compared to vector control; however, miR-200a 
combined with Ras did not significantly increase proliferation compared to miR-200a 
alone.  Ras alone showed the greatest increase in proliferating cells.  This indicates that 
stimulation of proliferation is not responsible for the interactive effect between Ras and 
miR-200a, and that Ras is unable to enhance the proliferative function of miR-200a. 
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We next examined these cells for changes in migratory ability, a cancer hallmark, 
and a phenotype frequently regulated by miR-200a and its family members.  miR-200a 
decreased trans-well cell migration of MCF10A cells compared to vector control (Figure 
17).  Ras alone greatly increased cell migration above vector control.  Cells expressing 
Ras in combination with miR-200a also showed decreased migration compared to Ras 
alone; however, these cells formed dense, three-dimensional colonies before and after 
migrating.  Inhibition of cell migration is consistent with the literature and miR-200a’s 
established function in regulation of EMT [124,186]. 
 When seeded in Matrigel extracellular matrix, MCF10A cells grow to form 
polarized acinar structures with a distinct hollow lumen, which resembles normal breast 
tissue development [190].  To gain insight into the potential effects of the cooperation of 
miR-200a with Ras on cell growth and morphology in the context of acinar structure 
formation, we seeded cells in Matrigel, and analyzed three dimensional acinus formation 
by confocal microscopy (Figure 18).  Acini were examined for changes in three 
characteristics:  morphology, E-Cadherin expression, and cleaved Caspase-3 expression.  
Acini were stained for E-Cadherin to facilitate inspection of morphological and structural 
changes, as well as changes in E-Cadherin expression and subcellular localization (Figure 
19). Vector control cells formed regular spherical structures with hollow lumen.  Cells 
expressing miR-200a alone formed regular spherical structures, with and without regular 
lumen clearance.  Cells expressing Ras alone formed very irregular and lobular three 
dimensional structures with loosely packed cells and partial lumen clearance.  Cells 
expressing miR-200a in combination with Ras formed densely packed, slightly irregular 
spherical structures with no lumen clearance.  Notably, in acini expressing Ras alone, or 
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Ras with miR-200a, E-cadherin was localized diffusely in the cytoplasm, rather than at 
the plasma membrane.  This is consistent with studies showing disruption of normal 
adherens junctions in transformed cells, and sequestering of E-Cadherin away from the 
plasma membrane in the cytoplasm [192,193].  In order to determine whether the cause 
of the loss of lumen clearance in response to miR-200a expression was loss of apoptosis, 
we examined levels of cleaved Caspase-3 in matrigel-seeded cells allowed to grow as 
acini for 3 days (Figure 18).  Acini containing vector or miR-200a expressed high levels 
of cleaved Caspase-3 and showed normal lumen clearance.  This is in contrast to the loss 
of lumen clearance in acini expressing miR-200a after seven days (data not shown).  
Acini expressing Ras alone formed lobular structures at 3 days, and expressed lower 
levels of cleaved Caspase-3.  Acini structures expressing Ras in combination with miR-
200a showed tightly packed structures with no lumen clearance, and little to no cleaved 
Caspase-3. Taken together, these results indicate that miR-200a alone decreases lumen 
clearance by increasing proliferation without decreasing apoptosis (Figures 16 and 19); 
however, miR-200a synergizes with Ras to inhibit apoptosis as evidenced by the dramatic 



















Figure 12.  miR-200a augments Ras-induced malignant cellular transformation. 
Figure 12.  miR-200a augments Ras-induced malignant cellular transformation.   
Soft agar colony formation:  bright field microscopy of MCF10A cells stably infected with the 
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Figure 13.  miR-200a augments Ras-induced malignant cellular transformation. 
Quantification of soft agar colony formation in Figure 12; 2000 MCF10A cells stably 
infected with miR-200a and the indicated oncogenes were plated in triplicate.  The 
data represents means of three independent experiments +/- standard error.   
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,  




miR-200a + p53dd 
Freq. G1  = 28.88 
Freq. S = 46.43 
Freq. G2  = 22.69 
p53dd 
Freq. G1  = 38.48 
Freq. S = 32.94 
Freq. G2  = 26.86 
miR-200a + cMyc 
Freq. G1  = 35.48 
Freq. S = 35.07 
Freq. G2  = 27.73 
cMyc 
Freq. G1  = 37.07 
Freq. S = 34.96 
Freq. G2  = 27.23 
miR-200a + Ras 
Freq. G1  = 50.15 
Freq. S = 16.98 
Freq. G2  = 27.23 
Ras + cMyc 
Freq. G1  = 55.52 
Freq. S = 24.59 
Freq. G2  = 17.56 
miR-200a 
Freq. G1  = 43.83 
Freq. S = 28.55 
Freq. G2  = 26.09 
Ras 
Freq. G1  = 47.70 
Freq. S = 26.94 
Freq. G2  = 23.35 
Vector 
Freq. G1  = 70.93 
Freq. S = 10.07 
Freq. G2  = 16.51 
Figure 14.  miR-200a increases cell cycle progression, but not in combination with 
oncogenes. 
Figure 14.  miR-200a increases cell cycle progression, but not in combination with oncogenes.   
Representative histograms of cell cycle distributions of MCF10A cells infected with the indicated 


























Figure 15.  miR-200a increases cell cycle progression alone, not synergistically 
with oncogenes. 
Figure 15.  miR-200a increases cell cycle progression alone, not synergistically 
with Ras.  Quantification of cell cycle distribution in Figure 6; MCF10A cells infected 
with the indicated oncogenes alone or in combination with miR-200a. 
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,  






















































Figure 16.  miR-200a mediated increase in proliferation is not enhanced by Ras.  
Cell proliferation curve of MCF10A cells infected with miR-200a, Ras, or miR-200a 
in combination with Ras.  Cell proliferation assayed by MTT assay.  Cells were plated 
in triplicate; data are means of three independent experiments +/- standard error. 
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,  































Ras Ras + miR-200a 
Figure 17.  miR-200a inhibits cell migration. 
 
Figure 17.  miR-200a inhibits cell migration.  Transwell cell migration of MCF10A 
cells infected with miR-200a, Ras, or miR-200a in combination with Ras and stained 














































Figure 18.  MCF10A cells form hollow acini in Matrigel 3 dimensional culture. 
 
Figure 18.  MCF10A cells form hollow acini in Matrigel 3 dimensional culture.  
Upper left:  Schematic of three dimensional acinus formed by MCF10A cells in 
Matrigel.  Black line indicates equatorial confocal plane of focus.  Upper right:  
Schematic of hollow lumen visualized by confocal microscopy focused at center line 
depicted in left diagram.  Lower:  representative image of acinar structures formed 












































  Figure 19.  miR-200a cooperates with Ras to inhibit apoptosis.  Three dimensional 
acinar formation after 5 days in Matrigel; MCF10A cells infected as indicated, stained 




miR-200a cooperates with the RalGEF Ras effector pathway 
Ras activity results in the activation of a wide array of downstream signaling 
pathways; however, the three main effectors that are activated by Ras are Raf, PI3K, and 
RalGEF [29].  We made use of three Ras mutants to determine the mechanism behind 
miR-200a cooperating with Ras to increase MCF10A cell transformation.  The T35S 
point mutation allows for activation of only the Raf-Erk effector pathway; the Y40C 
point mutation allows for activation of only the PI3K effector pathway, and the E37G 
point mutation allows for activation of only the RalGEF effector pathway (Figure 20).  
We expressed miR-200a along with each of these individual effector pathway mutations 
to determine which pathway miR-200a specifically cooperates with and assayed them for 
anchorage-independent growth in soft agar (Figure 21, 22).  Compared to T35S alone, 
miR-200a in combination with T35S caused a small, but insignificant increase in colony 
formation.  miR-200a in combination with Y40C did not cause an increase in colony 
formation compared to Y40C alone.  miR-200a caused a significant ten-fold increase in 
cells expressing both E37G and miR-200a compared to cells expressing E37G alone.  
Notably, un-mutated Ras formed more colonies than any of the effector mutants alone or 
combined with miR-200a, indicating that while miR-200a synergizes with the E37G 
mutant to enhance cell transformation, these two hits do not completely recapitulate the 
full effect of Ras. 
We next analyzed MCF10A cells expressing Ras effector mutants alone or in 
combination with miR-200a for changes in cell cycle progression (Figure 23).  T35S 
significantly decreased G1 phase arrest, but when miR-200a was added, the effect was 
ablated.  Y40C alone, or in combination with miR-200a did not show any change in cell 
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cycle progression, consistent with the lack of effect on colony formation.  E37G alone 
induced a modest but significant increase in G1 phase arrest.  However, E37G in 
combination with miR-200a significantly decreased G1 phase arrest, compared to both 
vector control and E37G alone, indicating that miR-200a induction of cell cycle 
progression contributes to its cooperation with RalGEF signaling in cell transformation. 
 We next analyzed the three dimensional growth in Matrigel of MCF10A cells 
expressing E37G or T35S Ras effector mutants alone and in combination with miR-200a 
to determine changes in structure and apoptosis (Figure 24).  Cells expressing E37G Ras 
mutant alone formed regular, round acini with hollow lumen, but had lower levels of 
cleaved Caspase-3 than the vector control (Figure 19,24).  When miR-200a was added, 
cells expressing E37G Ras mutant formed large, irregularly shaped structures with tightly 
packed cells and diffuse E-Cadherin staining; punctate cleaved Caspase-3 was visible 
throughout the structures, along with apoptotic cells; however, no lumen clearance was 
observed, similar to Ras alone.   Cells expressing T35S Ras mutant alone formed regular 
spherical acini with strong plasma membrane localization of E-Cadherin; cleaved 
Caspase-3 staining showed uncompromised apoptosis levels in these acinar structures, 
however, no lumen clearance was observed, possibly due to slower growth.  Cells 
expressing T35S in combination with miR-200a formed irregular acinar structures, most 
without lumen clearance; structures that did exhibit lumen clearance were part of larger, 
lobular structures, indicating irregular growth despite lumen clearance; plasma membrane 
localization of E-Cadherin was retained, and structures showed low levels of cleaved 
Caspase-3 staining.   
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These results indicate that miR-200a cooperates with E37G mutant to disrupt 
acinar growth; however, the change in acinar structure is likely due to increased 
proliferation rather than a change in apoptosis compared to E37G alone.  These effects 
were not seen when miR-200a was added to T35S, demonstrating that miR-200a does not 
cooperate with or enhance the effects of Raf signaling on acinar morphology.  Taken 
together, this strongly implicates physiological significance for the interaction between 





Figure 20.  Ras effector pathways. 
Figure 20.  Ras effector pathways.  Schematic of the 3 main effector pathways of 
Ras.  Indicated on the leftmost arrows are the activating point mutations that allow for 
activation of only that pathway.   
RalGEF Jnk Ral 
PDK1 Akt PI3K 




























  Figure 21.  miR-200a cooperates with the RalGEF pathway to increase cell 
transformation.  Soft agar colony formation assay of MCF10A cells stably infected 
with the indicated Ras effector mutants alone (left panels) or in combination with 




















Figure 22.  miR-200a cooperates with RalGEF pathway activation.   
Figure 22.  miR-200a cooperates with RalGEF pathway activation.  Quantification 
of soft agar colony formation in Figure 13; MCF10A cells stably infected with miR-
200a alone or in combination with the indicated Ras effector pathway mutants.  Cells 
were plated in triplicate.  Data represent means of three independent experiments +/- 
standard error. 
* p ≤ 0.05 compared to vector control, † p ≤ 0.05 compared to miR-200a,  
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 Figure 23.  miR-200a cooperates with the RalGEF pathway to induce cell cycle 














Figure 23.  miR-200a cooperates with the RalGEF pathway to induce cell cycle 
progression.   Cell cycle distribution analyzed by flow cytometry; MCF10A cells 
infected with the indicated oncogenes alone or in combination with miR-200a. 
* p ≤ 0.05 compared to vector control, € compared to E37G.  P-values calculated for 


















Figure 24.  miR-200a cooperates with RalGEF signaling to disrupt acinar growth. 
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  Figure 24.  miR-200a cooperates with RalGEF signaling to inhibit apoptosis and 
induce proliferation.  Three dimensional acinar formation after five days in Matrigel; 
MCF10A cells infected as indicated, stained for E-Cadherin (green, left panels) and 




miR-200a stimulates Akt and suppresses p53. 
To further elucidate the mechanism of miR-200a in malignant cell transformation, 
we analyzed MCF10A cells either transiently (Figure 25A) or stably (Figure 25B) over-
expressing miR-200a for known targets as well as potential downstream effectors.  
Similar to RK3E cells, Fog2 expression is decreased in MCF10A cells expressing miR-
200a, accompanied by an increase in Akt phosphorylation.  However, the miR-200a 
target Pten is not down-regulated in MCF10A cells.  We also analyzed p53 levels in 
unchallenged and Doxorubicin-challenged MCF10A cells to determine the effect of miR-
200a in the apoptotic response.  In unchallenged cells, basal levels of p53 were 
unchanged between vector control and miR-200a expressing cells.  In response to 
Doxorubicin, p53 protein expression and phosphorylation increased in vector control 
cells, but not in cells expressing miR-200a.  Because of the involvement of miR-200a in 
the Akt pathway and its cooperation with the RalGEF pathway, we also analyzed protein 
expression and phosphorylation levels of Erk, the third Ras effector pathway.  In cells 
transiently expressing miR-200a, Erk expression and phosphorylation levels decreased 
compared to vector control; however, in cells stably expressing miR-200a, expression 
and phosphorylation levels of Erk were unchanged, indicating that miR-200a does not 




































Figure 25.  miR-200a stimulates Akt signaling and inhibits p53.   
Figure 25.  miR-200a stimulates Akt signaling and inhibits p53.  (A) Western Blot 
of MCF10A cells transiently transfected with miR-200a.  (B) Western Blot of 





miR-200a synergizes with the RalGEF signaling pathway to induce tumorigenesis. 
We subcutaneously injected immunocompromised nude mice with MCF10A cells 
expressing miR-200a in combination with the T35S mutant, or with the E37G mutant and 
histologically analyzed resulting tumors [194].  MFC10A cells expressing miR-200a in 
combination with the E37G mutant were the only cells that formed subcutaneous tumors 
(Figure 26).    Transformed MCF10A cells recapitulate human proliferative mammary 
disease in subcutaneous tumors in nude mice [188]; thus we stained tumor sections with 
H&E and histologically examined them for abnormal tissue structures (Figure 27).  All 
tumors were vascularized, regardless of size (Figure 27A), and duct formation was either 
absent (Figure 27C) or severely abnormal (Figure 27B).  Defined structures of dense 
connective tissue were present with intermittent sections of loose connective tissue that 
infrequently contained small structures resembling ducts, but without regular epithelial 
lining (Figure 27B). The highly irregular tissue structure and loss of normal duct 
formation resembles the histology seen in invasive carcinoma of human mammary 
proliferative disease.  The severity of tissue architecture disruption indicates the strong 
potential of the interaction between miR-200a and the RalGEF pathway to contribute to 
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miR-200a 
T35S vector miR-200a 
Figure 26.  miR-200a cooperates with the RalGEF pathway to induce 
tumorigenesis in immunocompromised mice. 
Figure 26.  miR-200a cooperates with the RalGEF pathway to induce 
tumorigenesis in immunocompromised mice.  (A) Average tumor size after 10 
weeks in nude mice subcutaneously injected with the indicated Ras effector pathway 
mutants alone or in combination with miR-200a.  (B)  Representative images of tumor 
formation.  Each mouse was injected in each flank with MCF10A cells stably over-
expressing a Ras effector mutant alone in one flank, and MCF10A cells stably over-
expressing the same Ras effector mutant in combination with miR-200a in the other 





































Figure 27.  miR-200a cooperates with the RalGEF pathway to induce tumor 
pathology resembling invasive human proliferative breast disease. 
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  Figure 27.  miR-200a cooperates with the RalGEF pathway to induce tumor 
pathology resembling invasive human proliferative breast disease.   
A, B, C. Representative H&E staining of tumors formed by E37G+miR-200a 
MCF10A cells.  Tissue structures resembling human mammary histology are labeled 







miR-200a and EMT 
miR-200a was originally studied as a tumor suppressor and inhibitor of migration 
and metastasis because of its inhibition of EMT.  We verified that this new oncogenic 
role of miR-200a occurs alongside upregulation of epithelial markers.  Consistent with 
this, cells overexpressing miR-200a alone or in combination with Ras showed decreased 
migration compared to vector control or Ras alone, respectively.  In nude mice, miR-200a 
synergizes with the RalGEF pathway to form subcutaneous tumors with histology that 
resembles invasive proliferative breast disease.  This is especially notable because miR-
200a has been reported to be a crucial player in the maintenance of epithelial cell 
polarity, particularly in the mammary gland [195].  The disruption of tissue structure by 
the combination of miR-200a over-expression with RalGEF signaling highlights the 
significance of this interactive effect. 
miR-200a, Fog2 and Proliferation 
Only recently has the oncogenic role of miR-200a in proliferation been studied.  It 
directly targets Fog2 and positively regulates cell growth [102].  Following this, more 
evidence has revealed the important role of the miR-200 family and Fog2 in regulating 
PI3K activity in the context of insulin signaling, indicating the significance of the miR-
200a/Fog2/PI3K axis in human health [196-199]. We have demonstrated that miR-200a 
transforms immortalized rat RK3E kidney epithelial cells and augments Ras 
transformation of immortalized human MCF10A cells.  This is consistent with a study by 
Zhao et al. demonstrating that activated PI3K complements Ras activation in 
113 
 
transformation of human mammary epithelial cells (HMECs) [200].  Our study shows 
that miR-200a overexpression decreases Fog2 expression and increases Akt 
phosphorylation as Fog2 is a negative regulator of PI3K activity.  Notably, PI3K/Akt 
signaling is one of the three main Ras-effector pathways, and we show that miR-200a 
augments Ras transformation of MCF10A cells.  More specifically, miR-200a 
complements the RalGEF/Jnk pathway to enhance colony formation in soft agar.  
miR-200a alone significantly increased cell proliferation and cell cycle 
progression.  Yet miR-200a in combination with Ras did not significantly increase cell 
proliferation or cell cycle progression out of G1 above that seen in cells overexpressing 
miR-200a alone.  Indeed, miR-200a in combination with Ras had a negative interaction 
effect on cell proliferation compared to Ras alone.  This indicates that stimulation of the 
pro-proliferative PI3K/Akt pathway is not responsible for the synergistic effect between 
Ras and miR-200a, indicating that Ras activates PI3K/Akt signaling to high levels that 
can not be further enhanced by miR-200a suppression of Fog2.  Conversely, miR-200a in 
combination with RalGEF signaling causes a significant decrease in G1 cell cycle arrest 
compared to RalGEF alone, indicating that miR-200a induction of cell cycle progression, 
rather than inhibition of apoptosis, is important for cooperation with RalGEF signaling. 
It is crucial to note that the phenotypic response to miR-200a overexpression in 
the context of Ras signaling may be cell- or tissue-type specific.  miR-200a has a well-
studied dichotomous role in cancer, and both its overexpression and down-regulation 
have been associated with increased tumorgenesis [105,119].  These studies 
demonstrating miR-200a’s contradictory functions emphasize the potential for tissue-
specific signaling and pathway interactions. 
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miR-200a, p53, and Inhibition of Apoptosis 
Supporting the synergy between Ras and miR-200a are the changes in acinar 
structure and intra-luminal apoptosis.  miR-200a alone did not decrease cleaved Caspase-
3 levels in the lumen of acini.  Although lumen formation was curtailed when Ras was 
expressed alone, cleaved Caspase-3 staining was not ablated, indicating that an increase 
in proliferation, rather than loss of apoptosis was responsible for the lack of lumen 
clearance in MCF10A-Ras acini.  However, when Ras and miR-200a were expressed 
together, cleaved Caspase-3 levels decreased dramatically, indicating that miR-200a 
synergizes with Ras to elicit inhibition of apoptosis.  Loss of apoptosis is mechanistically 
supported by western blot analyses showing down-regulation of p53 protein and 
phosphorylation levels by miR-200a in MCF10A cells.  miR-200a is known to directly 
target p53 and inhibit apoptosis [53], and expression of p53dd in MCF10A cells has been 
shown to inhibit apoptosis and cause an EMT-driven loss of normal acini formation 
including normal structure and lumen clearance [190].  However, miR-200a is a strong 
inhibitor of EMT, indicating that miR-200a disruption of p53 leading to reduced 
apoptosis is the dominant force in disrupting normal lumen clearance, not EMT.   
miR-200a Cooperates with RalGEF 
 The Raf-Erk effector pathway is considered largely responsible for Ras-
mediated transformation of murine cells [201,202]; however, differences exist between 
the transformation of human cells and rodent cells. The RalGEF effector pathway alone is 
able to recapitulate approximately 60% of Ras-induced transformation of human 
embryonic kidney cells, but was not able to induce tumorigenesis in vivo [203].  
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Consistent with this, our study shows that expression of the E37G mutant (activating the 
RalGEF effector pathway) alone in MCF10A cells was not able to induce tumorigenesis.  
However, we show that the combination of miR-200a over-expression and RalGEF 
pathway activation is enough to induce malignant cell transformation and subcutaneous 
tumor formation in vivo. This effect is not seen when miR-200a overexpression is 
combined with either mutants activating the PI3K pathway (Y40C mutant) or the Raf/Erk 
pathway (T35S mutant).  miR-200a overexpression alone was insufficient to induce 
colony formation or tumorigenesis, indicating that the combination of Akt activation and 
loss of p53 is not enough to effect transformation.  By cooperating with the RalGEF 
pathway to transform cells, miR-200a demonstrates that loss of p53 syngergizes with 
gain of Akt and RalGEF signaling to transform MCF10A cells.  This is consistent with a 
study showing transformation of human embryonic kidney cells by the cooperation of 
PI3K and RalGEF signaling with loss of p53 in a setting of Rb loss and telomerase gain 
of function [18].  Rangarajan et al. also reaffirm the importance of RalGEF signaling in 
human cell transformation compared to mouse cell transformation relying more heavily 
on the Raf effector pathway [18].    Overall, this shows that suppression of p53 and 
stimulation of Akt by miR-200a is enough to transform immortalized Rat cells, but not 
immortalized human cells; however, the addition of RalGEF signaling enables miR-200a 
to transform immortalized human MCF10A cells and induce tumorigenesis. 
In summary, our results show that miR-200a enhances Ras-mediated 
transformation of human cells.  This is the first study that delineates miR-200a’s function 
in malignant cell transformation.  We also show that miR-200a synergizes with the 
RalGEF-activating E37G Ras effector mutant to transform MCF10A cells and induce 
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tumorigenesis in vivo, providing mechanistic insight into the mechanism of action of this 
dichotomous miRNA.  By determining that cooperation with RalGEF is necessary for 
miR-200a-mediated cell transformation, we have illuminated a new, specific role for 
miR-200a in malignancy.  Furthermore, we anticipate that future studies examining the 
concomitant genetic changes occurring during malignant transformation will thoroughly 




CONCLUSIONS AND FUTURE DIRECTIONS 
Conclusions 
Cancer is a deadly disease that claims the lives of over half a million people every 
year in the United States.  Cancer is a progressive disease that begins with malignant cell 
transformation and culminates in metastasis.  It is critical to understand cancer initiation 
to aid in cancer prevention, and to develop methods to detect and diagnose early stages of 
cancer before deadly metastasis develops. 
 In this study, we employed a biphasic approach to determine miRNA involvement 
in malignant cell transformation.  The first step involved profiling our library of 366 
miRNAs to determine the role of miRNA clusters in four major cancer signaling 
pathways.  In this screen, we were able to provide a panoramic view of the effects of 
miRNAs on AP-1, NF-κB, p53, and c-Myc signaling.  In our miRNA cluster profiling 
study, we found that 200b~429, which includes miR-200a, down-regulates p53 activity.  
miR-200a was demonstrated to directly target p53, reduce protein levels, and inhibit 
apoptosis.  These results provide a strong foundation for the study of miR-200a as an 
oncomiR.  miRNA clusters frequently function via cooperative targeting that involves 
cluster members suppressing different effectors of the same signaling pathway, or 




Given miR-200a’s role in p53 suppression, it is likely that the entire 200b~429 cluster, as 
well as its family cluster 200c~141, plays a role in regulating apoptosis. 
 The second phase of this study was an epithelial cell screening assay to determine 
the ability of miRNAs to transform epithelial cells.  The immortalized RK3E cell line in 
particular was employed because of its growth as a monolayer that becomes three 
dimensional foci formation upon transformation with an oncogene.  From this assay, we 
found that miR-200a transforms RK3E cells.  We further characterized the transformative 
potential of miR-200a in the untransformed, immortalized human MCF10A cell line.  We 
found that miR-200a enhances Ras-mediated transformation of this cell line.  These 
results are consistent with a study that shows that knockdown of the high endogenous 
miR-200a levels in MCF7 breast cancer cells reduces soft agar colony formation [62].  
Mechanistic studies showed that miR-200a suppresses p53 protein levels and 
phosphorylation, as well as Fog2 protein levels.  Fog2 is a direct target of miR-200a and 
a negative regulator of PI3K activity.  miR-200a overexpression increased proliferation 
and cell cycle progression, but when Ras was added, we did not see a combinatorial 
effect.  This indicates that the anti-apoptotic signaling mediated by miR-200a suppression 
of p53 is responsible for enhancing Ras-induced transformation. This enhancement of 
Ras-mediated cell transformation implicates a potential role for miR-200a in Ras-driven 
malignancies, for example pancreatic cancer.  Further characterization of the mechasnism 
of action of miR-200a showed that miR-200a cooperates with the RalGEF effector 
pathway of Ras to induce soft agar colony formation and tumorigenesis in 
immunocompromised mice.  Inability of miR-200a to transform immortalized human 
MCF10A cells indicates that miR-200a stimulation of Akt activity and suppression of 
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p53 is not enough to transform MCF10A cells; however, the addition of RalGEF 
signaling in this setting induces transformation.  These results demonstrate a role for 
miR-200a in malignant cell transformation and provide a specific cellular context where 
miR-200a acts as an oncomiR rather than a tumor suppressor.  
In summary, this work reveals a new role for miR-200a in malignancy.  We show 
that miR-200a transforms immortalized rat RK3E cells, and when over-expressed with 
Ras, it transforms immortalized human MCF10A cells.  Taken together, these results 
indicate that miR-200a is pro-oncogenic.  We also show that miR-200a transforms 
MCF10A cells by cooperating with RalGEF pathway activation, but not activation of the 
PI3K/Akt or Raf/Erk pathways, which are the other two main effectors of Ras.  This 
transformative ability underscores the importance of miR-200a in the Akt and p53 
pathways.  Our results highlight the importance of the specific cellular environment when 
characterizing the function of miR-200a.  In particular, it is crucial to evaluate miR-200a 




This study focuses on the transforming ability of a single miRNA, miR-200a, 
which exists both as a member of a miRNA cluster, as well as a member of a five-
membered miRNA family.  Future studies focusing on the individual effects of miR-200 
family members will provide insight into the function of this family, and studies in which 
the miR-200 family is expressed at disease-relevant levels or ratios will provide an 
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understanding of the dysregulation of this entire family, as well as its individual 
members, within the context of cell transformation.   
Noncoding RNAs 
 The field of noncoding RNAs is rapidly expanding to encompass lncRNAs, 
piRNAs, ceRNAs…the list continues ad nauseam.  These novel regulators provide 
insight into the control of miRNA-based gene silencing.  For example, ceRNAs, or 
competing endogenous RNAs, are highly abundant mRNAs that act as miRNA sponges, 
titrating potent miRNAs out of the pool of gene regulators, thereby unsilencing miRNA 
targets while the ceRNAs themselves experience insignificant downregulation by these 
targeted miRNAs.  The presence of ceRNAs provides another level of cell context in 
which miR-200a is functioning.   
Global gene expression effects 
MicroRNA studies initially began as a race to discover as many new direct 
miRNA targets as possible without follow-up experiments to determine physiological 
relevance.  As studies have progressed, it has become clear that miRNA effects are likely 
not due to targeting one single gene, as miRNAs have the potential to 1) target multiple 
genes at once and 2) be regulated by their own targeting mechanism e.g. by ceRNAs.  
Thus it is crucial to view the “one target per miRNA” perspective with caution, and 
future studies should take a more global approach to profile changes in gene expression 
in response to changes in miRNA levels.  This study identifies p53 and Fog2 as key 
targets of miR-200a in the context of cell transformation; however, it is highly probable 
that miR-200a targets a plethora of genes to regulate multiple signaling pathways.  This 
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view is further complicated by the need to characterize the combined effects of the entire 
miR-200 family. 
Clinical Relevance 
Because of the dichotomous role of miR-200a in cancer initiation, progression, 
and metastasis, it has the potential to serve as a context-specific biomarker for staging 
cancer diagnoses or providing prognostic information.  For example, early stage 
carcinomas overexpressing miR-200a alone may be less aggressive than tumors 
overexpressing miR-200a in the setting of constitutive Ras activation, or increased 
RalGEF signaling.   
In particular, changes in expression—both elevations and decreases—of miR-
200a are frequently implicated in breast cancer, providing an array of evidence for the 
contradictory role of mir-200a in cancer.  Future studies focused on miR-200a expression 
in breast cancer tumor samples stratified into cohorts based on prognosis, survival, and 
estrogen and progesterone receptor status will provide significant insight into the specific 
contexts in which miR-200a inhibits or contributes to cancer initiation and progression. 
Understanding the prognostic potential of this miRNA, and by extension the entire miR-
200 family, would provide clinicians with the tools to better diagnose and treat cancer 
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